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Abstract 
 
 Ubiquitination is a common post-translational modification that is critically 
important to many different cellular pathways. Dysfunction of ubiquitin pathways 
can disrupt various cellular processes that eventually cause diseases such as 
Huntington’s disease (HD).  Unlike typical ubiquitination, which happens at lysine 
residues of substrates, Ube2W attaches ubiquitin in an atypical manner: to the N-
termini of substrates. Disordered N-termini are believed to represent the 
preferred substrates for Ube2W. In chapter 1, I review recent studies of typical 
lysine ubiquitination and atypical ubiquitination, including Ube2W-mediated N-
terminal ubiquitination. I also review ubiquitin pathways implicated in HD, since 
the disordered N-terminus of the disease protein, Huntingtin (Htt), is a compelling 
candidate substrate for Ube2W and the focus of later studies. I then describe the 
results of two research projects that investigate Ube2W in vitro and vivo functions. 
In chapter 2, using mice in which the Ube2W is knocked out, I present evidence 
that Ube2W is important for early postnatal survival and plays significant roles in 
in multiple organ systems; I also provide in vivo evidence that supports the view 
that Ube2W preferentially targets disordered substrates. In chapter 3, using 
cultured cells and genetic crosses in mouse models, I show that Ube2W 
regulates the solubility of mutant Htt. Ube2W deficiency significantly increases 
! ix!
levels of soluble Htt monomers and reduces Htt-mediated neurotoxicity. Chapter 
4 concludes the dissertation with thoughts of future studies. Taken together, this 
dissertation provides in vivo evidence supporting Ube2W’s ability to N-terminally 
ubiquitinate misfolded proteins, which is key to multiple cellular pathways and 
organ functions. This dissertation establishes novel insights to the in vivo 
functions of Ube2W and N-terminal ubiquitination.!
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Chapter One: Ubiquitin pathways and their role in 
neurodegenerative diseases 
 
1.1 ABSTRACT 
The conjugation of ubiquitin to proteins, a process known as ubiquitination, is 
critical to many cellular processes. Different types of ubiquitination result in a 
wide range of fates for substrate proteins including proteasomal degradation, 
altered cellular location, and regulation of enzymatic activity. Typically, ubiquitin 
is conjugated to one or more lysine residues in a substrate protein. Non-
canonical ubiquitination to other amino acids or to the amino-termini of substrates 
can also occur, but is poorly understood. The specific cellular functions of non-
canonical ubiquitination, and amino-termini ubiquitination in particular, are not yet 
determined. In this introductory chapter, I review recent discoveries regarding 
non-canonical ubiquitination, including its potential functions. Furthermore, 
because ubiquitin pathways play an important role in most neurodegenerative 
diseases associated with protein aggregation and accumulation and will be the 
focus of chapter three of this thesis, I will review the effect of traditional and non-
canonical ubiquitination on a well-known disease target, the Huntington’s disease 
protein, Huntingtin (Htt). 
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1.2 INTRODUCTION 
Ubiquitination is a common post-translational modification that can occur 
to most proteins, leading to different fates for the modified protein depending on 
the specific type of ubiquitination. An evolutionarily conserved protein that is 76-
amino acids in length, ubiquitin (Ub) is conjugated to substrate proteins in an 
energy-dependent, sequential reaction: 1) conjugation is initiated by activation of 
Ub via the Ub-activating enzyme, E1, which forms a high-energy thio-ester bond 
between C-terminal glycine of Ub and the active site thiol of E1; 2) the Ub-E1 
complex then transfers the activated Ub to a Ub conjugating enzyme, E2, which 
also forms a thio-ester bond between Ub and E2 as in the Ub-E1 complex; 3) 
Ubiquitin ligase (E3) then comes into play, transferring Ub from the E2 to a 
substrate via different mechanisms depending on the subtype of E3. A series of 
ubiquitination events can happen to different sites on a substrate or to another 
Ub already attached to the substrate, generating monoubiquitination and 
polyubiquitination, respectively. The ubiquitination process is kept in check by 
deubiquitinating enzymes (DUBs) that act to cleave pre-formed Ub chains and 
recycle free Ubs and possibly edit the types of polyubiquitin chains added to 
substrates (Fig 1). 
Typically, Ub is covalently attached to free ε-amino groups on lysine side 
chains. Additional Ub molecules then can be further attached to any of the seven 
lysine residues of Ub, giving rise to polyubiquitin chains that contain a wide range 
of topologically distinct Ub-Ub linkages. Emerging evidence, however, indicates 
that Ub also can be covalently attached to the α-amino group of a protein’s 
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amino-terminus, the hydroxyl group of serine, threonine or tyrosine residues and 
the thiol group of cysteine residues(1). These latter kinds of ubiquitination events, 
termed non-canonical ubiquitination, are understudied compared to the typical, 
canonical lysine ubiquitination.  
Taking into consideration these different Ub-chain lengths, linkages and 
substrate attachment sites, dramatically different kinds of ubiquitination can occur. 
The variety of ubiquitination pattern is mainly achieved by different combination 
of E2/E3 pairs. The regulation of Ub attachment is achieved collaboratively 
between E2s and E3s. At least 38 E2s are encoded in the human proteome and 
play an essential role in the diversity of Ub chain assembly. E2s determine chain 
initiation or elongation, the types of linages in polyubiquitin chain, and, in some 
cases, substrate site preference. My thesis investigates the in vivo function of an 
intriguing E2, Ube2W. Ube2W is the only E2 shown to specifically carry out N-
terminal ubiquitination.  
The various forms of Ub signals regulate a wide spectrum of cellular 
functions: protein proteasomal degradation; autophagy; DNA damage response; 
multi-protein complex assembly; subcellular localization; enzymatic activity and 
the inflammatory response. Given Ub’s importance to many physiological 
processes, specific alterations in Ub signaling can result in drastic effects 
contributing to various human diseases. For example, dysregulation of ubiquitin 
pathways is important in neurodegenerative diseases, which are often 
characterized by protein accumulation and aggregation. Defects in ubiquitin 
systems, including Ubiquitin-Proteasome System (UPS), are present in 
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neurodegenerative diseases such as the polyglutamine (polyQ) diseases which 
are caused by a CAG repeat expansion in the protein coding sequence of the 
disease gene, resulting in an expanded stretch of glutamine residues in the 
disease protein. In polyQ diseases such as Huntington’s disease (HD), the polyQ 
expansion causes protein misfolding. Because of the defective ubiquitin system 
in polyQ disease, misfolded disease proteins tend to oligomerize, accumulate 
and become detrimental to neuronal health. The exact reason for ubiquitin 
pathway alteration in neurodegeneration is still unclear, but more insights to the 
ubiquitin system can be beneficial and hopefully can uncover potential therapies 
to these diseases.   
 
1.3 CANONICAL LYSINE-MEDIATED UBIQUITIN PATHWAYS 
1.3.1 Monoubiquitination 
As stated in introduction, ubiquitination can occur on a single residue or 
several residues of a substrate protein, resulting in monoubiquitination or multi-
monoubiquitination (Fig 1). To specify whether the Ub will be further ubiquitinated 
(i.e. form a polyubiquitin chain), different E2 and E3 partners have evolved to 
achieve these outcomes. For example, proliferating cell nuclear antigen (PCNA), 
a key enzyme in DNA repair response, can be targeted for monoubiquitination on 
Lys164 by the E2 Rad6 and the E3 Rad18. Such monoubiquitination signals the 
recruitment of multiple polymerases to initiate DNA repair. In contrast, the E2 
Ubc13/MMS2 and the E3 Rad5 can further extend the Ub chain on 
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monoubiquitinated PCNA and such polyubiquitination is important to DNA 
repair(2–4).  
Recent evidence suggests that the E2 is more important in such 
discrimination and that E2s can preferentially mediate chain initiation, chain 
elongation or both. Different E2s can partner with the same E3 and substrate, 
resulting in initial monoubiquitination or subsequent polyubiquitination. The 
BRCA1-BARD1 E3 ligase recruits any of the four E2s, UbcH6, Ube2E2, UbcM2 
and Ube2W, to monoubiquitinate BRCA1, whereas it recruits the E2s 
Ubc13/MMS2 and Ube2K to polyubiquitinate BRCA1(5–9). Although the exact 
mechanism for this discrimination is not understood, the structures around the E2 
catalytic region and substrate lysines are both considered to be important 
regulators(10, 11). 
The biological functions of monoubiquitination extend far beyond protein 
degradation. One important function of monoubiquitination is the regulation of 
endocytosis. A well-known example is epidermal growth factor receptor (EGFR): 
once activated, EGFR is rapidly multi-monoubiquitinated (monoubiquitination 
events occurred on multiple substrate lysines) by Cbl E3 ligase family(12, 13) 
which leads EGFR to interact with ubiquitin binding domains (UBDs) that lie 
within adaptor proteins such as clathrin coat proteins and EGFR substrate 15 
(EPS15)(14). This interaction triggers the assembly of monoubiquitinated EGFR 
molecules into clathrin-coated vesicles. In the meantime, adaptor proteins such 
as EPS15 undergo EGFR-coupled monoubiquitination by NEDD4 (E3), further 
facilitating EGFR endocytosis and subsequent lysosomal degradation(15, 16). 
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Monoubiquitination can also regulate enzymatic activity of substrate 
proteins. As a key switch of cellular differentiation and growth, Ras signaling is 
tightly regulated by monoubiquitination. Monoubiquitination of Lys147 in K-Ras 
inhibits GAP-mediated GTP hydrolysis, thus increasing its biological effects(17–
19). Comparatively, monoubiquitination of Lys117 in H-Ras increases GTP-GDP 
exchange, thus activating H-Ras via a different mechanism than K-Ras(20).  
Monoubiquitination is also crucial in DNA damage response. After DNA double 
strand breaks (DSB), the histone H2A variant H2AX is one of the first proteins 
recruited to the DSB sites to initiate DNA damage repair. RNF2 and BMI1-
mediated H2AX monoubiquitination is required for its phosphorylation and 
subsequent DNA repair, and a lysine mutation that abolishes H2AX 
monoubiquitination impairs its recruitment to DNA damage loci(21). Fanconi 
Anemia pathway is another major DNA repair pathway that is highly regulated by 
FANCD2 monoubiquitination. Ube2W, the focus of my thesis, together with 
Ube2T, are able to monoubiquitinate FANCD2 in vitro, but only Ube2T knockout 
renders cells more prone for mitomycin-C induced DNA crosslinking(22–24).  
The protein that is the focus of this thesis, Ube2W, is an E2 that 
preferentially monoubiquitinates substrates on their N-terminal amino group(25). 
Although the exact in vivo function of such modification is unknown, the lessons 
from literature suggest a wide range of biological functions for monoubiquitination 
that are not limited to proteasomal degradation. 
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1.3.2 Polyubiquitination 
After the first Ub is attached to the substrate, subsequent cycles of 
ubiquitination can target the amino groups on Ubs already attached to the 
substrate, thus generating polyubiquitin chains. There are eight amino groups in 
each Ub molecule: an α-NH2 at the N-terminus and the ε-NH2 of lysines at 
position 6, 11, 27, 29, 33, 48 and 63. Much like the mechanism in distinguishing 
monoubiquitination or polyubiquitination, Ub chain linkage preference can be 
specified by E2s: examples include K11-specific Ube2S, K48-specific Ube2K, 
K63-specific Ube2N-Ube2V1, and UbcH5 that can produce K11, K48 and K63 
linkages. E2s are not involved in formation of Ub-Ub linkages via the N-terminal 
methionine (Met1); rather, Met1-linked Ub chains are generated by the linear 
ubiquitination assembly complex (LUBAC) that includes HOIL-1L, HOIP and 
sharpin.  
The various types of Ub linkages serve as distinct cellular signals (Fig 2). 
The best-studied type of polyubiquitination is K48-linked Ub chain. A stretch of 
more than four K48-linked Ubs on a substrate typically serves as a signal for 
proteasomal targeting and degradation(26). Several E2s are known to generate 
such chain linkages: Ube2K, Ube2G2 and cdc34. Mutations in key regulatory 
domains of these E2s result in loss of specificity towards K48-linked Ub chain (9, 
27). Once K48-linked polyUb is attached to a substrate, the conjugate must be 
targeted to the cell’s degradation machinery by chaperone or Ub adapter proteins, 
which recognize and bind to the polyubiquitin stretch. Valosin-containing protein 
(VCP) is a chaperone and Ub adapter protein, which physically interacts with and 
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shuttles poly-ubiquitinated substrates to the proteasome to facilitate their 
degradation(28). Ubiquilin-2 (UBQLN2) is another shuttle protein that contains 
both UBA domain and UBL domain, through which they can interact with 
polyubiquitinated substrates and the proteasome. UBQLN2 and related ubiquilins 
can bring polyubiquitinated substrates to the proteasome. Dominant acting 
mutations in VCP or UBQLN2 can result in the accumulation of poly-ubiquitinated 
proteins and carrier patients suffer from neurodegenerative diseases such as 
Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)(29, 30).  
The 26S proteasome can be divided into the catalytic 20S core protease 
(CP) and 19S regulatory particle (RP). Cooperatively, the 19S RP base and lid 
recognize K48 linked Ub chains, cleave off Ub moieties, and unfold and import 
substrate to the CP for degradation. Cooperatively, the chymotrypsin-like, 
trypsin-like, and caspase-like activities of the 20S CP cleave substrate proteins 
into small peptides(31). Similarly, K11-linked Ub chain modification on target 
substrate can also result in proteasomal degradation and plays an important 
function in mitosis progression(10, 32). In contrast, K63-linked ubiquitination has 
more diverse non-proteolytic functions: DNA repair(33), stress response(34, 35), 
signal transduction(36, 37) and intracellular protein trafficking(36).  
M1-linked Ub chains are implicated in NF-κB activation: LUBAC promotes 
linear poly-Ub of RIP2 and serves as an activation signal for IKK kinase complex. 
Such activation enables IκB polyubiquitination and subsequent proteasomal 
degradation(38). Alterations in LUBAC and M1-linked Ub signals are implicated 
in many diseases including variety of solid tumors (lung cancer, breast cancer, 
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prostate cancer and melanoma) and immune disorders(39). Patients with 
inactivation or deficiency of heme-oxidized IRP2 Ub ligase-1 (HOIL-1, LUBAC 
component) suffer from chronic autoinflammation and susceptibility to bacterial 
infections(40).  
Taken together, polyubiquitination has a wide variety of cellular functions 
that are largely determined by types of ubiquitin chain linkages.  
 
1.4 NON-CANONICAL UBIQUITINATION  
1.4.1 Ubiquitinations on internal non-lysine residues 
 In addition to amino groups, Ub can also be attached to hydroxyl groups of 
serine, threonine or tyrosine residues and the thiol group of cysteine residues(1). 
In the past decade, numerous targets have been identified to undergo this non-
canonical ubiquitination. Peroxisomal import factor Pxp5 was the first identified 
substrate of cysteine ubiquitination(41, 42). Lysineless Pxp5 can still be 
ubiquitinated and Pxp5’s N-terminal amine is naturally blocked by co-translational 
acetylation. Both lines of evidence suggest that Pxp5 ubiquitination occurs at 
internal non-lysine residues. Cysteine ubiquitination was postulated because 
reducing agents, which break thioester bonds, can disrupt Pxp5 
ubiquitination(43). Indeed, when Cys11 is mutated to arginine, Pxp5 
ubiquitination is abolished. Pex20p, a Pxp5 related protein, was later found to be 
ubiquitinated on cysteine as well(44). Cysteine ubiquitination of Pxp5 and 
Pex20p is critical to their cellular localization: it serves as a signal to recycle the 
proteins from the peroxisome to cytosol(41, 43–45). Additionally, Ngn2 is a 
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proneural transcriptional factor that can be ubiquitinated at many potential 
ubiquitination sites, including cysteine, lysine, N-terminus, serine and threonine. 
However, unlike Pxp5 and Pex20p where cysteine ubiquitination plays a 
nondegradative signaling role, cysteine ubiquitination on Ngn2 is sufficient for its 
proteasomal degradation(46, 47).  
 Ubiquitination on hydroxyl groups of serine, threonine or tyrosine of the 
Major Histocompatibility Complex I (MHC I) heavy chain is critical to its stability; 
mutations of these residues not only reduce its polyubiquitination, they also 
stabilize the protein(48). Ngn3 is another example of a protein modified by this 
type of ubiquitination. Unlike Ngn2, which is ubiquitinated on a cysteine residue, 
Ngn3 ubiquitination occurs at serines and threonines, serving as a degradation 
signal(49).  
Taken together, ubiquitination on internal non-lysine residues occurs to a 
limited number of proteins and can target these substrates to various destinies 
including protein degradation and altered cellular localization. Although only a 
few proteins have been reported to be modified on these non-canonical sites, 
with the recent advance in mass spectrometry, these internal non-lysine 
ubiquitinations are increasingly identified by the resultant signature peptide(50). 
Identifying more substrates of this type of ubiquitination will lead to a better 
understanding of the function of this modification. 
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1.4.2 N-terminal ubiquitination 
When it remains unmodified, a protein’s N-terminus provides an additional 
free amino group beyond internal lysines. Ub can be attached to the α-amino 
group via the same mechanism as occurs with conjugation to lysine residues. 
For a small subset of proteins, when all lysine residues are chemically 
mutated or deleted, ubiquitination still takes place and may serve as a 
degradation signal. When the free α-amino group is blocked, by a bulky tag or 
chemically ablation, these substrate proteins could no longer be ubiquitinated 
and thus were stabilized(51–55). Among these proteins, MyoD was the first 
identified example of N-terminal ubiquitination: lysine-less MyoD can still be 
ubiquitinated and degraded. Proteasomal inhibition can completely block the 
degradation of lysine-less MyoD and lead to an accumulation of ubiquitin-
conjugated MyoD. Moreover, when the free α-amino group is blocked with 
carbamylation or 6 myc tags, Ub can no longer be attached to MyoD and MyoD 
becomes stabilized both in vivo and in vitro(52). These findings ruled out 
canonical lysine-mediated ubiquitination of MyoD since ubiquitination still occurs 
when all lysines are removed, leaving only one intact amino group on the N-
terminus of MyoD. N-terminal tagging physically blocked Ub access to the free α-
amino group. Taken together, MyoD is the first example of a now growing list of 
proteins that can be N-terminally ubiquitinated. 
Using similar experimental approaches, researchers identified several 
other examples of N-terminal ubiquitination: ataxin-3(56), cyclin G1(57), Epstein-
Barr virus latent membrane protein 1 (LMP1)(53), LMP2A(51), Extracellular 
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signal-regulated kinase 3 (ERK3)(57), the inhibitor of DNA binding 1 (ID1) 
protein(58), ID2(59), p19(60), p21(55) and peroxisome proliferator activated 
receptor γ co-activator 1a (PGC1a)(61). In the case of ataxin-3, ERK3 and p21, 
there is even more convincing direct evidence from mass spectrometry (MS): a 
fusion peptide directly linking the N-terminal methionine of substrate and the C-
terminal glycine of Ub was identified in vivo(55, 56).  
Furthermore, there are 14 Naturally Occurring Lysine-Less Proteins 
(NOLLPs) encoded in the human proteome and 111 NOLLPs in the viral 
proteome(62). Lacking the lysine residue that is target for canonical ubiquitination, 
Ub can only be attached to non-lysine residues including the N-terminus. Indeed, 
p16INK4a and HPV-58 E7 both proved to be substrates for N-terminal 
ubiquitination and can be targeted for proteasomal degradation(62).  
Currently, all but two known N-terminal substrates (ataxin-3 and LMP2A) 
can be targeted for proteasomal degradation by N-terminal ubiquitination via 
K48-linked Ub chain. Among the substrates, cyclin G1, p16INK4a, p19 and p21 are 
key regulators governing the cell cycle: cyclin G1 is a key regulator of cyclin-
dependent protein kinases (CDKs) and is implicated in G2/M arrest in response 
to DNA damage(63, 64). p16INK4a, p19 and p21 are three well-studied tumor 
suppressors that inhibit CDK4 and CDK6, so that they arrest cell cycle at G1 or 
G2(65); loss of function of either gene can lead to dysregulation of cell cycle and 
results in various cancers including melanomas and germ cell tumors(66). Since 
all of them can be targeted for degradation by N-terminal ubiquitination, a 
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potential important function of N-terminal ubiquitination is the regulation of cell 
proliferation.  
Lessons from classic lysine ubiquitination inform us that ubiquitination is 
more than just a degradation signal. Accordingly, the potential function of N-
terminal ubiquitination in non-degradation pathways needs further investigation. 
 
1.4.3 Ube2W and N-terminal ubiquitination 
Ube2W is the only E2 known to mediate N-terminal ubiquitination(56, 67). 
It is a class I E2 that consists of the catalytic UBC domain without any N-terminal 
or C-terminal extensions. Ube2W can function with various ubiquitin ligases 
including the C terminus of Hsc-70-interacting protein (CHIP) and the 
BRCA1/BARD1 complex to mono-ubiquitinate select substrates at their amino-
termini or internal lysines(25, 56, 68–70). Ube2W’s structure reveals that it is an 
unique E2 in two major respects. First, unlike other E2s, Ube2W has an unique 
binding pocket preceding the highly conserved C91 which is present in all 
members of this E2 family. Within this pocket, Ube2W has a histidine (H83) in 
place of the conserved asparagine residue. This asparagine critically stabilizes 
the oxyanion intermediate after E2-Ub lysine attack and stabilizes the loop 
preceding the active site(71). When H83 is mutated to asparagine, Ube2W can 
no longer ubiquitinate its documented substrates (e.g. CHIP and tau)(56). 
Second, except H83, Ube2W shares a highly conserved UBC core structure with 
other E2s, however, its C-terminal residues N136-W145 form a highly disordered 
region positioned beneath the active site C91 (Fig 3). This disordered C-terminus 
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is critical to substrate interaction, as mutation in one of the residues, W144E, 
abolishes Ube2W’s Ub-transfer activity towards tested substrates (ataxin-3, CHIP, 
RBP8 and tau) (68). These characteristic structural features of Ube2W may 
provide clue to its unique activity as an N-terminal ubiquitinating E2. 
One Ube2W substrate is ataxin-3, which is mutated in the polyglutamine 
disorder, Spinocerebellar Ataxia Type 3 (SCA3). Ataxin-3 was already known to 
be ubiquitinated by other E2s and CHIP at two lysine residues, K117 and K200. 
However, when Ube2W is present, Ub is instead attached to the N-terminus of 
ataxin-3 instead of these internal lysines. When carbamylation or a bulky GST 
tag is used to block ataxin-3’s α-amino group, Ub can no longer be attached to 
ataxin-3 by Ube2W. Mass spectrometry also identified the fusion of ubiquitin C-
terminus to ataxin-3’s N-terminus, providing direct evidence for N-terminal 
ubiquitination(56). The same experimental methods proved that SUMO-2 and 
CHIP also can be N-terminally ubiquitinated by Ube2W(67).  
Ube2W is a strict monoubiquitinating E2. Unlike LUBAC, which catalyzes 
M1-linked linear Ub chains, Ube2W does not extend the Ub chain. This 
observation is supported by the fact that Ube2W fails to show a noncovalent 
interaction with Ub whereas covalent interactions between E2s and ubiquitin are 
a common feature of ubiquitin chain-elongating E2s (6, 72–74). Interestingly, 
when a 13-amino-acid long human influenza hemagglutinin (HA) is added to the 
N-terminus of ubiquitin, Ube2W shifts its activity from monoubiquitination to M1-
linked linear polyubiquitination, indicating that the HA tag itself can be a robust 
substrate for Ube2W. The HA tag is highly mobile and disordered compared to 
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ubiquitin, suggesting that Ube2W prefers disordered substrates. To test this, 
glycine, the most flexible amino acid, was added to the N-terminus of ubiquitin; 
whereas 1 glycine did not alter Ube2W ubiquitination pattern, the addition of 3 
glycines allowed Ube2W to generate polyubiquitin chains, and chains of 5 and 7 
glycines further increased the production of polyubiquitin chains by Ube2W. This 
activity is lost when prolines, amino acids with bulky side chain, are instead 
added to the N-terminus. 
Despite these recent advances in understanding the activity of Ube2W as 
a N-terminal ubiquitinating E2, the physiological function of Ube2W-mediated N-
terminal ubiquitination was unknown before the start of my thesis. Although most 
substrates tested thus far can be targeted for degradation after N-terminal 
ubiquitination, whether this holds true in Ube2W-mediated N-terminal 
ubiquitination is unclear. Our unpublished data suggest that lysine-less ataxin-3 
is degraded nearly as efficiently as WT ataxin-3, suggesting either that Ube2W-
mediated ataxin-3 N-terminal ubiquitination does not play an important role in 
ataxin-3 degradation or that ataxin-3 N-terminal ubiquitination is limited in vivo.  
The microenvironment inside the cell is much more complex than in a test 
tube, especially when studying the N-termini of proteins. Besides ubiquitination, 
acetylation is another post-translational modification that targets amino groups of 
protein including at their N-termini. N-terminal acetylation has been well 
documented since the 1950s when researchers faced difficulty sequencing 
proteins using the Edman degradation method; they realized that acetylation can 
“block” protein N-termini from being recognized. In fact, a majority of proteins can 
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be N-terminally acetylated in some organisms: about 60% in yeast, 30% in D. 
melanogaster and 85% in human cells(75, 76). N-terminal acetylation prevents 
Ube2W from ubiquitinating these substrates.  
Recent evidence from TRIM5α and TRIM21 has provided insight to 
Ube2W’s effect on N-terminally acetylated molecules. Members of the tripartite 
(TRIM) family, TRIM5 and TRIM21 serve as antibody receptors that neutralize 
intracellular viruses(77). TRIM5α contains a RING domain, conferring upon it an 
additional E3 ligase activity. When it interacts with retroviral caspids, TRIM5α 
generates unanchored K63-linked Ub chains, which stimulate NF-κB 
translocation and induces antiviral gene expression(78, 79). TRIM21 itself can be 
polyubiquitinated with K63-linked chains and signals immune pathways. The N-
termini of both TRIM5α and TRIM21 are acetylated, rendering them inaccessible 
to Ube2W. However, Ube2W can still mono-ubiquitinate TRIM5α and TRIM21 on 
internal lysines (K45 and K50 of TRIM5α) identified by mass spectrometry. After 
Ube2W initiates the Ub chain, Ube2N/Ube2V2 is recruited and extends K63-
linked chains. When deacetylating reagents chemically unblock TRIM5α N-
termini, Ube2W shifts its preference towards N-termini(69, 70). These results 
suggest that while Ube2W has a strong preference toward N-termini of proteins, 
when the α-amino group is inaccessible, Ube2W is capable of mediating 
ubiquitination to some lysine residues. 
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1.5 UBIQUITIN PATHWAYS IN HUNTINGTON’S DISEASE 
 Ubiquitin pathways are implicated in many neurodegenerative diseases 
including Huntington’s disease (HD). For my thesis studies, I became particularly 
interested in HD because Huntingtin (Htt), the disease protein in HD, is 
intrinsically misfolded at its N-terminus. This property suggests that Htt is an 
attractive candidate substrate for Ube2W-mediated N-terminal ubiquitination. The 
function of Htt N-terminal ubiquitination is unknown. Here, I review the current 
knowledge of ubiquitin pathways involved in neurodegenerative diseases 
including HD.  
 
1.5.1 Polyglutamine diseases and other neurodegenerative diseases 
Accumulation of ubiquitinated proteins is commonly observed in 
neurodegenerative diseases. Inclusion body (IB) formation is a characteristic 
pathological hallmark shared by many neurodegenerative diseases such as 
Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral 
Sclerosis (ALS), and the polyglutamine (polyQ) diseases. It is believed that 
dysfunction of the ubiquitin-proteasome system (UPS) or defects in other 
ubiquitin-dependent pathways contributes to the accumulation of ubiquitinated 
proteins, which are then recruited to inclusion bodies. Currently, however, there 
is disagreement regarding the cause of neuron death and the potential 
pathogenic role of inclusions in neurodegeneration. Whether the inclusion itself is 
directly toxic, simply a marker of abnormal protein accumulation, or even a 
protective strategy adopted by neurons to “wall off” extra protein load, remains 
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under debate. Regardless, dysregulation of ubiquitin-mediated protein quality 
control pathways is implicated in many of these neurodegenerative diseases. 
Mutations in genes encoding numerous ubiquitin pathway proteins cause various 
neurodegenerative diseases. For example, loss of function mutation in CHIP, a 
E3 ligase that works with Ube2W, causes ataxia(80, 81). Loss of Ube3A, an E3 
ligase that specifically generates K48-linked Ub chains, causes Angelman 
syndrome, which presents as ataxia, myoclonus and other behavioral 
phenotypes(82, 83).  
The polyQ diseases include at least nine neurodegenerative disorders: six 
forms of spinocerebellar ataxias (SCA) type 1, 2, 3, 6, 7, and 17; (SCA3 is also 
known as Machado-Joseph disease, or MJD/SCA3); Huntington's disease (HD); 
dentatorubral pallidoluysian atrophy (DRPLA); and spinal and bulbar muscular 
atrophy (SBMA). PolyQ diseases are characterized by the pathological 
expansion of a CAG trinucleotide repeat in the protein-coding region of the 
otherwise unrelated disease genes, which is translated to an expanded polyQ 
stretch in the disease proteins. The biochemical properties of expanded polyQ 
promote abnormal folding, oligomerization and aggregation of the disease protein. 
Protein quality control systems, including chaperones and ubiquitin-proteasome 
system (UPS), are important cellular machineries coping with this aberrant 
protein load(113). In normal conditions, chaperones help proteins fold correctly 
and the UPS targets unwanted or misfolded proteins for degradation and keeps 
them at a healthy level inside the cell. Several lines of evidence have implicated 
perturbations in protein quality control systems in various polyQ diseases.  
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Molecular chaperones are involved in several key cellular pathways, 
including folding of nascent proteins, refolding of misfolded or denatured proteins 
and translocation of proteins(84). Heat shock proteins (HSPs) comprise the 
majority of chaperones and are central to protein folding and refolding. Induction 
of HSPs by Heat shock factor protein-1 (Hsf1), a transcription factor, significantly 
reduces polyQ inclusion formation and cytotoxicity in cultured cells and animal 
models of HD and SBMA(85–87), while deficiency of Hsf1 accelerates and 
exacerbates disease phenotypes (86, 87). Cell-based time-lapse microscopy has 
shown that increasing Hsf1 concentration leads to decreased mutant huntingtin 
(Htt) IB formation(88). There is some disagreement about how Hsf1 regulates Htt 
inclusion perhaps because conclusions were based on results in different model 
systems(85–88). Studies using more physiologically precise disease models, 
such as knock-in mouse models, may provide more definitive evidence. Hsp40 
and Hsp70 are two major HSPs that have been shown to regulate misfolded 
polyQ proteins. They have been shown consistently to decrease IB formation and 
suppress toxicity in various polyQ models, including SCA1, SCA3, SBMA and 
HD(84, 89–96). Therapeutic approaches using chaperones have been 
extensively investigated. Small molecules such as 17-AAG and geldanamycin, 
which can activate Hsf1, have been shown to ameliorate polyQ aggregation, 
disease severity and neurodegeneration in both cellular and animal models(97–
99).  
In the case of the UPS, although multiple pieces of evidence suggest UPS 
involvement in polyQ inclusion formation and disease progression, there is 
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uncertainty regarding the primary cause of protein accumulation. Some studies 
suggest that a significant problem in polyQ diseases is proteasome 
dysfunction(100–103). PolyQ expansion induces polyQ-containing peptides that 
are capable of clogging and inhibiting normal proteasome activity(100, 101, 103). 
Other studies suggest otherwise, arguing instead that mutant Htt can be 
degraded efficiently in cultured cells(104, 105). However, only proteasome 
function is measured in these scenarios without taking into account of the whole 
UPS, which includes E1, E2, E3 and DUBs. To test the function of UPS, degron 
reporters such as UbG76V and CL1 are fused to fluorescent protein so that UPS 
activity can be measure quantitatively by fluorescence(106–109). CL1 degron is 
a highly destabilizing tag targeting fusion protein for degradation through UPS. In 
cellular models of HD, introducing CL1 degron showed an accumulation of 
fluorescent signal, indicating decrease of UPS activity(109, 110). UbG76V is an 
ubiquitin mutant that binds protein N-terminally and serves as a degradation 
signal through UPS. The G76 mutation disables Ub removal by DUB and enables 
subsequent polyubiquitination(111). In R6 mice where human mutant Htt is 
constitutively overexpressed, no global UPS impairment was observed(112, 113); 
however, when HttQ94 expression is acutely induced, a transient UPS impairment 
is observed in mouse striatum(113). Thus, transient and constitutive expression 
of mutant Htt result in completely different UPS responses. It is possible when 
mutant Htt is constitutively expressed, other compensatory mechanisms, such as 
chaperone system, are recruited to handle misfolding protein load; another 
possibility is that such long-term UPS impairment is too minimal to reach the 
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threshold of the limited detection methods. Taken together, UPS impairment is 
implicated in HD and other polyQ diseases.  
It is important to keep in mind that proteasomal degradation is only one of 
many potential outcomes of ubiquitination, as discussed earlier. Ubiquitinated 
proteins inside inclusion bodies contain K11-, K48- and K63-linked Ub chains. 
K11- and K48-linked Ub chains are proteasomal degradation signals, while K63 
linked Ub chain has a wide range of non-proteolytic functions. Recent evidence 
suggests the potential involvement of K63-linked Ub chains in regulating 
inclusion formation. In cultured cells overexpressing disease proteins that cause 
AD, FTD/ALS or PD, K63-linked ubiquitination promotes the formation of 
inclusion bodies(114–117).   
To conclude, protein quality control systems are critically important in 
maintaining protein homeostasis; dysfunction in any of the key protein quality 
control systems can contribute to polyQ protein accumulation and cytotoxicity. 
Ubiquitin pathways including K11, K48 and K63 linked Ub chain modifications 
regulate polyQ protein stability and aggregation.  
 
1.5.2 Huntington’s disease and the disease protein, Huntingtin 
The final sections of this chapter review the recent discoveries on ubiquitin 
pathways involved in a specific polyQ disease, Huntington’s disease (HD). In HD, 
the CAG repeat expansion encodes a polyQ stretch in disease protein huntingtin 
(Htt). In individuals without an expansion, the polyQ length is between 10 and 35 
residues in length and may help regulate protein interactions and gene 
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transcription(118, 119). When the polyQ length exceeds a threshold of ~40 
glutamines, it causes disease(120). The severity of HD is polyQ length-
dependent as increasing repeat length correlates with earlier onset of disease, 
more severe clinical and pathological presentations(121, 122). The most 
common HD alleles bear 40-50 CAG repeats. HD patients with these lengths 
tend to manifest classic HD symptoms including involuntary movements such as 
chorea and dystonia, neuropsychiatric symptoms and cognitive deficits. Repeats 
greater than 50 CAG repeats in length tend to cause earlier onset, juvenile HD 
that often includes additional symptoms beyond the classic symptoms noted 
above, including seizures and generalized slowness of movement(123). HD is a 
slowly progressive disease usually leading to death within 20 years of symptom 
onset. Histopathologically, HD displays a progressive spreading pattern of brain 
involvement: initially, the brain region affected most prominently is the striatum, 
with preferential loss of medium spiny neurons that express dopamine D2 
receptors and the neurotransmitter enkephalin(124–127). The cerebral cortex 
also is involved as disease progresses but, unlike most other polyQ diseases, the 
cerebellum is relatively spared in HD(128–130).  
Like other polyQ diseases, polyQ-expanded Htt protein is highly misfolded. 
It exists as three distinct states in cells: soluble monomers, soluble oligomers and 
insoluble aggregates(25, 26) (Fig 4). Htt aggregates present as inclusion bodies 
in neuronal nuclei, perinuclear regions and neurites(131–133). 
Immunohistochemical studies revealed that these inclusion bodies contain N-
terminal fragments of Htt, ubiquitin, proteasomal components and numerous 
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other proteins (132). Lines of studies suggest that the N-terminus of Htt plays a 
key role in Htt processing: alteration or modification to Htt’s N-terminus can result 
in dramatic changes in Htt level, localization and inclusion formation. Firstly, the 
N-terminus of Htt is polyQ containing since the CAG expansion occurs within 
exon1 of Hdh gene, thus generating a polyQ stretch at the very N-terminus 
(starting from the 18th amino acid). Secondly, the first 17 amino acids (N17) of Htt, 
located immediately before the polyQ stretch, are critical to cytosolic localization 
of the protein. Through N17, Htt can bind to cytoplasmic membrane in order to be 
exported from nucleus(134–137). In vitro, N17 promotes the formation of 
oligomers and aggregation of mutant Htt(138, 139), but deleting N17 has also 
been shown to significantly increase Htt nuclear localization and worsen disease 
phenotype in a BAC-HD mouse model(140). Thirdly, multiple protein post-
translational modifications can occur at the N-terminus of Htt including 
acetylation, phosphorylation, SUMOylation and ubiquitination(141) (Fig 5). All 
four modifications are critical to Htt levels and cytotoxicity(142–145). 
To conclude, the HD disease protein Htt is intrinsically disordered at its N-
terminus, partly due to N17 and partly due to the polyQ stretch, and this disorder 
may be critical to regulating Htt levels, localization and inclusion formation.  

1.5.3 Huntingtin Ubiquitination 
The discovery of ubiquitin and proteasomal subunits in HD inclusion 
bodies supports the importance of ubiquitination and the UPS in HD 
pathogenesis. However, the roles of ubiquitination and the proteasome in HD are 
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not fully understood. To date, two main theories have been proposed: 1. 
Ubiquitinated mutant Htt can no longer be degraded by the proteasome, and thus 
accumulates as inclusion bodies(109, 110, 112, 146–148); 2. Ubiquitination of 
mutant Htt is a non-degradation signal, with proteasome subunits being 
secondarily recruited to inclusions as cell’s coping mechanism towards such 
mutant Htt accumulation(112, 149). These theories may not be mutually 
exclusive to and both may contribute to HD pathogenesis.  
The most straightforward possibility is that ubiquitinated mutant Htt is itself 
a proteasomal substrate. As discussed in the previous section, two proposed 
scenarios might contribute to the inclusion formation: a) the increased burden of 
misfolded protein overwhelms the UPS system; and b) long polyQ stretches, 
derived from Htt by proteolytic cleavage, clog the proteasome and inhibit its 
normal function. In both cases, a defective proteasome would accelerate the 
accumulation of mutant Htt. This idea is supported by multiple cell and animal 
models in which HD is modeled by expression of an N-terminal fragment of Htt 
(109, 110, 112, 146–148). However, mixed findings were achieved in a more 
physiologically precise mouse model: proteasome function remains unaltered in 
R6 mouse(112, 149). In a doxycycline-inducible HdhEx1 transgenic mouse, the 
UbG76V-GFP reporter accumulates when HdhEx1 expression is induced(113). So, 
up to now, there is still disagreement on the exact function of UPS in HD 
pathogenesis.  
Besides Ub monomers and proteasome subunits, inclusions of 
postmortem HD brain also stained positively with anti-K63-linked ubiquitin 
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antibodies(109, 143, 150). As described above, unlike K48-linked Ub chains, 
K63-linked Ub chains serve as a non-proteolytic signal. When nuclear mutant Htt 
is biochemically pulled-down, K63-linkage is found to be the main ubiquitination 
species(143). The existence of K63-linked mutant Htt favors the hypothesis that 
ubiquitination of Htt represents a non-proteolytic signal. When lysine 63 of 
ubiquitin is mutated to arginine (K63R), K63-linked Ub chain can no longer be 
formed. In HD cell models where the N-terminal fragment of Htt was 
overexpressed, coexpression of K63R ubiquitin significantly decreased 
polyubiquitination of mutant Htt. In the same model, when all other lysines except 
K63 of ubiquitin were mutated to arginines, there was an increase in mutant Htt 
polyubiquitination. Taken together, these results suggest that, at least in cell 
models, K63-linked Ub chains are the main type of mutant Htt ubiquitination(143). 
In vivo validation of this idea would be very valuable.  
However, the exact function of K63-linked Htt ubiquitination is still unclear. 
It has been postulated that K63-linked ubiquitinated Htt is caused by failed Htt 
degradation through K48-linked Ub chain(143, 150), since K63-linked 
ubiquitination has been linked to autophagic clearance of inclusions and 
accompanies UPS impairment(117, 151, 152). In another study, however, the 
presence of K63-linked Ub chains enhanced polyQ inclusions and targeted polyQ 
protein for subsequent autophagic clearance, thus contributing to the life cycle of 
IBs(116, 117). 
In addition to ubiquitination, SUMOylation may play an important role in 
HD pathogenesis. In HD patient brains, there is accumulation of SUMOylated 
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insoluble proteins including Htt(145). Like ubiquitination, SUMOylation is a post-
translational modification that targets protein lysine amino groups. Unlike the 
case with ubiquitination, N-terminal SUMOylation and other non-canonical 
SUMOylations have not been identified. SUMOylation participates in a wide 
range of cellular activities including the regulation of protein cellular localization, 
transcription control and protein interactions(153, 154).  There are four different 
SUMO isoforms in mammals: SUMO-1 and SUMO-2 are ~50% identical at a 
protein level, while SUMO-2 and SUMO-3 are nearly identical and SUMO-4 is a 
precursor form expressed in kidney, spleen and thymus(153, 155, 156). Similar 
to ubiquitination, substrate SUMOylation involves a cascade of enzymes: E1 
activating enzyme (AOS1/Uba2), E2 conjugating enzyme (Ubc9) and E3 ligases 
(PIAS, Pc2 and RanBP2). Since only one set of E1 (SAE1/SAE2) and E2 (UBC9) 
has been identified for SUMOylation, it is believed that E3s specify SUMOylation 
substrates.  PIAS (protein inhibitor of activated STAT) family is one of the best-
characterized SUMO E3 ligase families.  PIAS protein has RING finger domains, 
which assists in the attachment of SUMO to target substrates.   
Emerging evidence suggests that mutant Htt SUMOylation plays a key 
regulatory role in HD pathogenesis. Under stress conditions, Htt can be 
phosphorylated at S13 and S16 by inflammatory kinase (IKK) and lead to an 
increase polySUMOylation of truncated Htt (Httex1)(142). K6 and K9 of Httex1 are 
most susceptible to SUMOylation of both SUMO-1 and SUMO-2; mutation of 
these lysines can abolish Httex1 polySUMOylation(145). However, SUMO-1 and 
SUMO-2 showed a different regulatory role in mutant Htt aggregation and 
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inclusion. SUMO-1 modification of Httex1 reduces aggregation and solubilizes the 
protein(144). However, SUMO-2 is shown to cause Httex1 to insolubilize and 
accumulate. Overexpressing PIAS1, the E3 ligase for Htt SUMOylation, can also 
increase mutant Htt aggregation, reproducing the same cellular phenotype with 
SUMO-2 overexpression(145). In Httex1Q93 expressing drosophila model, 
knockdown of PIAS1 significantly decreases SUMOylation of Htt and rescues the 
eye degeneration(144, 145).  
In summary, both ubiquitination and SUMOylation of the N-terminal 
domain of Htt appear to participate in some manner in HD pathogenesis. 
However, non-canonical ubiquitination of Htt at its N-terminus has not been 
studied. Given the disordered nature of Htt’s N-terminal fragment, it is predicted 
to be a strong candidate target for non-canonical ubiquitination by Ube2W. The 
biological role of such modification is the key question of my second part of 
thesis. 
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1.6 FIGURE LEGENDS 
FIGURE 1. Process of ubiquitin conjugation 
Ubiquitin (Ub) conjugation is initiated by activation of Ub via the Ub-activating 
enzyme, E1, which forms a high-energy thio-ester bond between C-terminal 
glycine of Ub and the active site thiol of E1; 2) the Ub-E1 complex then transfers 
the activated Ub to a Ub conjugating enzyme, E2; 3) Ubiquitin ligase (E3) then 
comes into play, transferring Ub from the E2 to a substrate via different 
mechanisms depending on the subtype of E3. Deubiquitinating enzymes (DUBs) 
act to cleave pre-formed Ub chains and recycle free Ubs and possibly edit the 
types of polyubiquitin chains added to substrates. Additional ubiquitin molecules 
can be added onto the first to create polyubiquitin chains on substrate proteins. 
 
FIGURE 2. Different types of ubiquitin chains 
In canonical ubiquitin pathways, ubiquitin is usually attached to the ε‑amino 
group of lysine (K) residues in substrates. The transfer of a single ubiquitin to one 
(monoubiquitination) or multiple (multi-monoubiquitination) sites can inhibit 
interactions, change protein localizations, modulate protein activities or 
participate in DNA damage response. Ubiquitin itself contains seven lysine 
residues, which can function as acceptor sites for another ubiquitin moiety during 
ubiquitin chains formation. In addition, the amino terminus of a substrate-linked 
ubiquitin can serve as an acceptor for the formation of linear ubiquitin chains. 
Depending on the connection between linked ubiquitin molecules, ubiquitin 
chains can differ in structure and function. K48- and K11-linked ubiquitin chains 
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target proteins for degradation by the 26S proteasome. K63‑linked chains 
usually mediate autophagy, DNA damage repair or signal transduction. M1-linked 
ubiquitin chains involve in NF-κB activation. 
 
FIGURE 3. Ube2W’s unique structure allows N-terminal ubiquitination 
Ube2W (purple) has an unique binding pocket preceding the highly conserved 
C91 (yellow) which is present in all members of this E2 family. Within this pocket, 
Ube2W has a histidine (H83, cyan) in place of the conserved asparagine residue. 
Ube2W C-terminal residues N136-W145 form a highly disordered region 
positioned beneath the active site C91 and participate in substrate binding. 
These characteristic structural features allow Ube2W to function as an N-terminal 
ubiquitinating E2. 
 
FIGURE 4. Htt aggregation and related molecular pathogenesis of HD 
Full-length Htt usually undergo proteolytic cleavage that generates polyQ 
containing N-terminal fragment, which is highly misfolded. It exists as three 
distinct species in cells: soluble monomers, soluble oligomers and insoluble 
aggregates. Oligomeric and aggregating Htt are believed to be the toxic species 
in cells by inhibiting normal transcription, proteasome function, autophagy and 
normal organelle function. 
 
FIGURE 5. Post-translational modification of Htt N-terminus 
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Several amino acids of N-terminal Htt are subjected to post-translational 
modifications. Each modification is colored on the schematics: acetylation as 
blue pentagon, phosphorylation as green, ubiquitination, and SUMOylation as 
red. 
!
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Chapter Two: Ube2W deficiency causes multi-system 
defects in mice 
 
2.1 ABSTRACT 
Ube2W ubiquitinates amino-termini of proteins rather than internal lysine 
residues, showing a preference for substrates with intrinsically disordered amino-
termini. The in vivo functions of this intriguing E2, however, remain unknown. We 
generated Ube2W germline KO mice that proved to be susceptible to early 
postnatal lethality without obvious developmental abnormalities.  While the basis 
of early death is uncertain, several organ systems manifest changes in Ube2W 
KO mice. Newborn Ube2W KO mice often show altered epidermal maturation 
with reduced expression of differentiation markers. Mirroring higher Ube2W 
expression levels in testis and thymus, Ube2W KO mice showed a 
disproportionate decrease in weight of these two organs (~50%), suggesting a 
functional role for Ube2W in the immune and male reproductive systems. Indeed, 
Ube2W KO mice displayed sustained neutrophilia accompanied by increased G-
CSF signaling, and testicular vacuolation associated with decreased fertility. 
Proteomic analysis of a vulnerable organ, pre-symptomatic testis, showed a 
preferential accumulation of disordered proteins in the absence of Ube2W, 
consistent with the view that Ube2W preferentially targets disordered 
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polypeptides. These mice further allowed us to establish that Ube2W is 
ubiquitously expressed as a single isoform localized to the cytoplasm and that 
the absence of Ube2W does not alter cell viability in response to various 
stressors. Our results establish that Ube2W is an important, albeit not essential, 
protein for early postnatal survival and normal functioning of the multiple organ 
systems. 
 
2.2 INTRODUCTION 
Protein ubiquitination is critical to many cellular processes. The sequential 
action of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and 
ubiquitin ligase (E3) results in isopeptide bond formation between the carboxyl-
terminus of ubiquitin and an amino group on the substrate protein. Typically, this 
isopeptide linkage occurs through the ε-amino group of one or more lysine 
residues in the substrate (157), though linkage through non-lysine residues has 
also been described, including esterification on cysteine, serine and threonine 
residues as well as isopeptide bond formation with the α-amino group at the 
amino-terminus of substrates (46, 51–53, 59–62, 158).  
Different ubiquitination events can specify distinct fates for substrate 
proteins. Well established examples include a role for mono-ubiquitination in 
altering the localization or activities of targeted proteins (159), the role of K48-
linked poly-ubiquitin chains in targeting substrates for proteasomal degradation 
(32, 160), and the role of K63-linked Ub chains in recruiting binding partners that 
facilitate various cellular pathways including the stress response, DNA repair, 
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and intracellular trafficking (161). In contrast, the function of amino-terminal 
substrate ubiquitination is poorly understood. Thus far, this process has only 
been implicated in proteasomal degradation of a subset of proteins including a 
few naturally occurring, lysine-less proteins (NOLLPs): p16INK4a, Puma and 
Human Papillomavirus Oncoprotein-58 E7 (60, 62, 158, 162). 
Ube2W is the only E2 known to mediate amino-terminal ubiquitination (56, 
67). It can function with various ubiquitin ligases including the C terminus of Hsc-
70-interacting protein (CHIP) and the BRCA1/BARD1 complex (5, 25, 163) to 
mono-ubiquitinate select substrates at their amino-termini, with an apparent 
preference for substrates having intrinsically disordered amino-termini (68). In 
addition, mono-ubiquitination of FANCD2, which can be mediated by Ube2W(23), 
is critical for activation of the Fanconi Anemia (FA) tumor suppressor pathway in 
the DNA damage response (22, 159), but the role of Ube2W in DNA damage 
pathways is not well studied. Ube2W also forms noncovalent homodimers which 
are not essential to its ubiquitin transfer activity (164).  
Despite growing knowledge of the biochemical properties of Ube2W, its in 
vivo functions remain elusive. Here we generated and characterized Ube2W KO 
mice to facilitate study of the physiological functions of this enzyme.  
 
2.3 EXPERIMENTAL PROCEDURES 
Animals-Three Ube2W gene-trap ES cell clones (Ube2wtm1a(EUCOMM)Wtsi) 
were obtained from EuComm and used to generate Ube2W chimeras. Germline 
transmission of Ube2W gene trap was successfully obtained. Ube2W KO mice 
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were generated by intercrossing Ube2W heterozygous KO mice. All mice in this 
study were maintained on a pure C57BL/6 genetic background, housed in cages 
with a maximum number of five animals and maintained in a standard 12-hour 
light/dark cycle with food and water ad libitum. Genotyping was performed using 
DNA isolated from tail biopsy at the time of weaning. Ube2W KO genotype was 
determined by PCR amplification of a fragment of Ube2W gene. Mice were 
euthanized at specific ages, anesthetized with ketamine/xylazine, and perfused 
transcardially with phosphate-buffered saline. 
PCR primers-For Ube2W KO genotyping: 
5’AAAGGAAGAGCCCAGTATGGACCCT3’ and 
5’AGAGTCCCTGCAGCTATTAC3’.  
Ube2W For: 5’ATGGTTTCATCATGGCGTCAATGCAG3’;  
1-Rev: 5’GATATGACCATTGCTATACACATGAGG3’;  
2-Rev: 5’TCAGGTGACCATAGAACTCACATG3’;  
3-Rev: 5’TCAACAAGTGTCATCATGATACCACCA3’. 
Western blotting-Protein lysates from different organs were generated by 
lysis in radioimmunoprecipitation assay (RIPA) buffer containing protease 
inhibitors (Complete-mini; Roche Diagnostics, Indianapolis, IN), followed by 
sonication and centrifugation. The supernatants were collected, total protein 
concentration was determined using the BCA method (Pierce, Rockford, IL) and 
then stored at −80 °C. Forty microgram of total proteins per sample were 
resolved in 15% sodium dodecyl sulfate–polyacrylamide gel electrophoresis gels, 
and corresponding polyvinylidene difluoride membranes were incubated 
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overnight at 4 °C with primary antibodies: rabbit anti-Ube2W (1:1,000; 15920-1-
AP; Protein Tech Group), mouse anti-GAPDH (1:10,000; MAB374; Millipore), 
rabbit anti-Histone H3 (1:10,000; #9715; Cell Signaling Technology), rabbit anti-
Gα i-2 (1:1,000; sc-4222; Santa Cruz Biotechnology), mouse anti-Hsp90 (1:1,000; 
Enzo Life Sciences) and goat anti-protamine-2 (1:250; sc-23104; Santa Cruz 
Biotechnology). Bound primary antibodies were visualized by incubation with a 
peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody (1:10,000; 
Jackson Immuno Research Laboratories, West Grove, PA) followed by treatment 
with the ECL-plus reagent (Western Lighting; PerkinElmer, Waltham, MA) and 
exposure to autoradiography films.  
Histological analysis-All tissues were fixed overnight at room temperature 
in 10% neutral buffered formalin, transferred to 70% EtOH, processed, and 
paraffin embedded. For immunohistochemical staining, tissue was sectioned at 
5$µm, deparaffinized, and rehydrated prior to antigen retrieval in boiling citrate-
based buffer (0.01$mol/L citric acid, pH 6.8). Endogenous peroxidases were 
quenched with 3% H2O2, followed by blocking in 5% goat serum and incubation 
with primary antibodies (Keratin 1 1:1000 , AF109, Covance, cat#PRB-165P; 
Keratin 5 1:2000, AF138, Covance cat# PRB-160P; Keratin 10 1:1000, Covance, 
cat# PRB-159P; loricrin 1:1000, Covance, cat# PRB-1459). Bound antibodies 
were detected with the Vector M.O.M. peroxidase (Vector Laboratories, 
Burlington, CA), using SigmaFast diaminobenzidene as a peroxidase substrate 
(Jackson ImmunoResearch, West Grove, PA) 
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Flow-cytometry-Cells were isolated from thymus, spleen, liver, and lymph 
nodes (axillary, brachial, and inguinal pooled) by passing through a 70 um nylon 
mesh filter into a 50ml conical tube. Blood was collected in EDTA-coated tubes, 
spun, and plasma was collected for multiplex analysis. Cells were resuspended 
in PBS and layered over lympholyte M to isolate viable lymphocytes. All cell 
preparations were ACK lysed and washed before analysis. For surface staining, 
cells were suspended in PBS with 2% FCS containing Fc Block (50 ng/ml) prior 
to incubation with fluorochrome-conjugated Abs (anti–mouse Ly-6C, AL21, BD; 
anti–mouse Ly-6G, 1A8, BD; anti–mouse CD11b, M1/70, eBioscience; anti–
mouse CD11c, N418, eBioscience; anti–mouse CD4, RM-45, eBioscience; anti–
mouse CD45, 30-F11, eBioscience; anti–mouse CD19, MB19-1, eBioscience; 
anti–mouse CD8, 3-6.7, eBioscience and anti–mouse MHCII (I-A/I-E), 
M5/114.15.2, eBioscience. The stained cells were analyzed with a FACSCanto II 
flow cytometer using FACSDiva software (v6.1.3, Becton Dickinson). Data were 
analyzed using FlowJo software (v9.3.2, TreeStar).  
Bead-based multiplex analysis-Plasma levels of G-CSF and GM-CSF 
were measured with customized multiplex magnetic bead based arrays (EMD 
Millipore) according to the manufacturer’s protocol. Data were collected using the 
Bio-Plex 200 system (Bio-Rad Laboratories). Standards were run in parallel to 
allow quantification of individual factors. The data shown indicates levels that fell 
within the linear portion of the corresponding standard curve. 
Differential proteome analysis using tandem mass tag (TMT) labeling and 
mass spectrometry-Protein lysates from 4-week-old mice testis were generated 
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by lysis in RIPA buffer containing protease inhibitors (Complete-mini; Roche 
Diagnostics, Indianapolis, IN), followed by sonication and centrifugation. The 
supernatants were collected and total protein concentration was determined 
using the BCA method (Pierce, Rockford, IL). Enzymatic digestion with trypsin 
and TMT labeling was performed essentially according to the manufacturer’s 
protocol (Thermo Scientific).  100 mg of peptide from each sample was labeled 
with TMT labeling reagents. The peptides from 3 wild type samples were labeled 
with TMT reagent channels 126, 127 and 128.  Peptides from 3 KO samples 
were labeled with TMT reagent channels 129,130 and 131.  Further processing 
of these samples using 2D-LC was done as described below. 
Peptides were reconstituted in strong cation exchange (SCX) buffer A (5 
mM KH2PO4, pH 3, 5% acetonitrile) and separated on a Polysulfoethyl A column 
(1 x 150 mm, 5 mm particle size, Thermo Scientific) using Dionex Ultimate 3000 
RSLC nano system at a flow rate of 50 ml/min.  Elution buffer B consisted of 
buffer A with 1 M NaCl.  A linear gradient of 35% buffer B over a period of 45 min 
followed by a 5 min wash with 100% Buffer B and re-equilibration with buffer A 
for 20 min was used.  Approximately 50 ug of peptides were separated per 
injection.  An on-line 214 nm UV detector guided the collection and pooling of 
fractions. 
The SCX fractions with 214 nm absorbance were desalted using in-line m-
Precolumn (5 mm x 300 mm inner diameter, C18 PepMap100, 5 mm, Thermo 
Scientific) and loaded directly onto a nano-RP column (Acclaim PepMap RSLC, 
15 cm x 75 mm inner diameter, 2 mm C18 media).  Peptides were separated 
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using acetonitrile/0.1% formic acid gradient system (2-30% acetonitrile over 50 
min followed by 95% acetonitrile wash for 5 min) at a flow rate of 300 nl/min on a 
Dionex Ultimate 3000 RSLC nano system.  Eluted peptides were directly 
introduced into Orbitrap Fusion Tribrid ETD mass spectrometer (Thermo Fisher 
Scientific) equipped with nano-flex source.  The mass spectrometer was set to 
collect a survey spectrum in the Orbitrap with a resolution of 60,000 followed by 
data-dependent HCD spectra on most abundant ions for the next 3 seconds.  For 
HCD, normalized collision energy was set to 35, maximum inject time was 120 
ms, maximum ion counts were set to 1e5 and product ions were analyzed in 
Orbitrap cell (resolution 15,000). 
Protein identification and quantification was performed using Proteome 
Discoverer 1.4 (Thermo Fisher Scientific).  The data was searched against a 
mouse protein database, a subset of UniProtKB (51629 entries), by considering 
trypsin enzyme specificity, and a maximum of 2 missed cleavages.  Precursor 
and product ion tolerance were set to 20 ppm and 0.02 Da respectively.  
Carbamidomethylation of cysteines and TMT labeling of lysines and peptide N-
termini are considered as fixed modifications.  Allowed variable modifications 
included oxidation of methionine and deamidation of asparagine and glutamine 
residues.  Percolator algorithm was used for discriminating between correct and 
incorrect spectrum identification.  The false discovery rate (FDR) was calculated 
at the peptide level and peptides with <1% FDR were retained. The quantification 
was performed using the reporter ion intensities which were extracted using 
Proteome Discoverer.                 
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Protein disorder analysis-Disorder was examined using the IUPred long 
(Dosztanyi et al., 2005; Dosztanyi et al., 2005) and DisEMBL (Linding et al., 2003) 
disorder prediction algorithms. Primary sequences for all proteins included in our 
disorder analysis were obtained from UniProt (The UniProt Consortium, 2015). 
Specifically, 3,905 protein sequences were obtained from the Mus musculus 
reference proteome file (Proteome ID: UP000000589, accessed on 4/28/2015), 
while 598 isoform sequences were retrieved from the UniProt isoform file 
(accessed on 5/23/2015). Of the total population of 4,503 proteins, those with 
completely defined primary sequences were included in our disorder assessment, 
while 76 proteins with ambiguous and/or undetermined amino acid residues were 
excluded. Within the remaining 4,427 proteins, protein length varied from 35 
amino acids (Transcription elongation factor A N-terminal and central domain-
containing protein; UniProt accession: A2AFP8) to 33,467 amino acids (Titin; 
UniProt accession: E9Q8K5).  Following the collection of disorder scores, a 
binary classification of “disordered” or “ordered” was assigned to each residue 
using algorithm-specific threshold values of disorder. To characterize disorder we 
chose to examine the percentage of disordered amino acid residues as well as 
continuous length disorder (CLD) both in N-terminal regions and in full-length 
sequences. Regions with CLD were defined as any sequence of two or more 
consecutive amino acids with individual disorder scores above the algorithm-
specific threshold value. The two-sided Kolmogorov-Smirnov test was used to 
compare the percent disorder distribution in the target and reference populations; 
p-values less than 0.05 were deemed significant. 
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Primary and secondary cell culture-Tail skin biopsies (3 to 5 mm) were 
obtained and cultured as follows: Skin samples were washed with PBS and 
ethanol, then diced, and digested overnight in collagenase type II (400 U/ml; 
1,600 U total per tail; Gibco-Invitrogen, Carlsbad, CA) dissolved in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal 
bovine serum (HyClone, Logan, Utah), antibiotics, and fungizone (complete 
medium). Incubation was at 37°C with 10% CO2. After overnight collagenase 
treatment, cells were separated from remaining tissue by filtering through a 45-
micron mesh, centrifuged, and resuspended in complete medium. Approximately 
2.5 × 105 cells in 5 ml of medium were seeded into tissue culture flasks of 25-cm2 
surface area, and this was called passage 0. A complete media change was 
made after 3-4 days. 7 days after cell isolation the cultures were trypsinized 
(using 0.05% trypsin) and placed into 75-cm2 flasks (0.6x106 cells) or 175-cm2 
flasks (1.2 × 106 cells). Each culture was passaged at a 7-day interval, with 
complete media changes being made on day 4 between passages. Cells used in 
the assays described were confluently plated at ∼105 cells/well in the third 
passage. 
Stress assays-Stress assays were performed as previously described 
(165) with slight modifications. Briefly, cells were plated confluently (10,000 
cells/well) into 96-well plates, allowed to adhere overnight. For the glucose 
deprivation assay cells were washed with PBS and then media containing 
differing amounts of glucose was added with the cells incubated for 6 hours. 
Survival was measured at the 6-
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washed with PBS and given media consisting of DMEM with only BSA added for 
24 hours. Cells were dosed with stressor for 6 h, after which cells were washed 
with PBS and returned to the DMEM media containing only BSA as a supplement. 
Survival was measured the following day by WST-1 (Roche) reduction. Stressors 
used in study: Thapsigargin and Tunicamycin are both from Calbiochem (EMD 
Chemicals, San Diego, CA); Cadmium Chloride is from Fluka (Sigma/Aldrich); 
MMS is from Aldrich (Sigma/Aldrich, St Louis, MO); Hydrogen peroxide, glucose 
and ammonium chloride are from Sigma (St Louis, MO) 
 
2.4 RESULTS 
Production of Ube2W KO mice 
To produce Ube2W KO mice, we acquired three EuComm ES cell lines 
bearing the targeting vector (Fig 6A-i) [EPD0156-4- C08, -C07, and -G06], two of 
which (C07 and C08) contained euploid chromosome counts. Blastocysts from 
C07 and C08 were injected into pseudopregnant females to produce chimeric 
mice. Upon breeding of chimeric mice, black progeny were selected for 
genotyping to confirm germ line transmission (data not shown). To generate 
“Floxed” Ube2W mice with the potential to engineer conditional knockout mice, 
we crossed mice with Flp recombinase-expressing mice to delete the lacZ and 
Neo cassette (Fig 6A-ii). Further crosses to Cre recombinase-expressing mice 
resulted in deletion of exon 3 of Ube2W, a critical 103bp exon whose absence 
leads to a frame shift causing premature termination of the protein and loss of 
!! 47#
functional Ube2W expression (Fig 6A-iii). Ube2W heterozygous KO mice were 
then bred to produce progeny of all three genotypes (Fig 6B). 

Ube2W is a widely expressed, predominantly cytoplasmic protein 
Little is known about the expression of Ube2W and its subcellular 
localization. The availability of Ube2W KO mice allowed us to analyze Ube2W 
expression in vivo. Lysates from different tissues were immunoblotted with a 
polyclonal anti-Ube2W antibody. A single, major immunoreactive protein of 
approximately 16 kDa was detected in every WT tissue examined but was absent 
in KO mice (Fig 6C). Among tissues examined, the testes, pancreas and thymus 
displayed the highest Ube2W expression, while the heart and liver showed the 
lowest Ube2W expression. 
The cross-reactivity of existing anti-Ube2W antibodies to other proteins 
limits their utility in immunofluorescence studies to assess subcellular localization 
of Ube2W. Instead, we used cell fractionation to define its intracellular residence. 
Cell extracts obtained from mouse embryonic fibroblasts (MEFs) were 
fractionated into membrane, cytosol and nuclear fractions by differential 
centrifugation (see EXPERIMENTAL PROCEDURES). Ube2W partitioned in the 
cytosolic fraction, showing little expression in membrane and nuclear fractions 
(Fig 6D). Similar results were obtained for extracts derived from mouse brain 
lysates (data not shown). In addition, human myc-tagged Ube2W equivalent to 
the mouse protein was transiently expressed in transfected HEK293 cells to 
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visualize subcellular localization. Human Ube2W also showed a diffuse 
cytoplasmic pattern with little staining in the nucleus (Fig 6E). 
 
Isoform 1 is the major expressed Ube2W isoform in mouse 
As shown in Figure 2, three potential protein isoforms of Ube2W are 
predicted in mouse: Isoforms 1 and 3 each contain six coding exons while 
isoform 2 has seven coding exons, two of which are unique to isoform 2. All three 
isoforms share exons 1-3 (Fig 7A, yellow) and exon 5. Isoforms 2 and 3 contain a 
shortened exon 4 that lacks the first 79bp of exon 4, resulting in a frame shift that 
alters the carboxyl-terminal half of the predicted protein (Fig 7A, green). Isoform 
2 also skips exon 6 and uniquely contains exons 7 and 8 that would encode a 
different protein segment (Fig 7A, red). In isoform 3, the stop codon in exon 6 
occurs further downstream because of the frame-shift in exon 4. 
To elucidate which isoforms are expressed in vivo, first strand cDNA was 
generated from WT and Ube2W KO MEFs, the latter to ensure the specificity of 
PCR amplification. Specific primer pairs were used to amplify and identify the 
three predicted Ube2W isoforms. The forward primer, identical for all three 
isoforms, binds exon 1. Reverse primer 1 (Rev-1) binds the extended exon 4 
present only in isoform 1, resulting in PCR amplification of an isoform 1 product 
differing in size in WT versus KO cells. PCR products of the expected size for 
isoform 1 were observed (Fig 7B) and confirmed by sequencing. Reverse primer 
2 (Rev-2) binds to exon 8 and thus can only amplify isoform 2, generating 
different size products for WT and KO cells.  No PCR products corresponding to 
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isoform 2 were observed (Fig 7B).  Due to the similarity between isoforms 1 and 
3, there is no specific primer pair for isoform 3. Isoforms 1 and 3 can be 
distinguished, however, by the longer PCR product for isoform 1 reflecting its 
extended exon 4. Predicted isoform 3 was not detected in WT or KO cells (Fig 
7B).  
These results indicate that, at least in MEFs, isoform 1 is the predominant 
if not only expressed form of Ube2W.  Because Ube2W protein runs as the same 
size protein in all tissues examined, we suspect that isoform 1 is the major 
expressed isoform in most if not all tissues. 
 
Methionine 30 is the transcriptional start site for Ube2W 
The Ube2W murine transcript contains two possible start codons, each 
with predicted Kozak sequences. Either or both could be used as the initiating 
site for translation. The predicted encoded proteins, termed here Met1 and Met30, 
have expected molecular weights of 20.7 kDa and 17.3 kDa, respectively. To 
determine which start site initiates translation of the single Ube2W protein 
species detected in mouse, we cloned the two predicted forms of Ube2W isoform 
1 into pcDNA3.1 from WT MEFs, and expressed them in transfected HEK293 
cells. Lysates from cells overexpressing Met1 or Met30 were analyzed on anti-
Ube2W immunoblots, run adjacent to lysates from WT, heterozygous and 
homozygous Ube2W KO MEFs for size comparison. (Transiently expressed 
Ube2W is highly overexpressed in these cells, and the low level of endogenous 
human Ube2W in HEK293 cells is not detectable in this short exposure.)  Ube2W 
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in MEFs electrophoresed identically to overexpressed Met30 at an apparent 
molecular weight of ~16 kDa, the same size as Ube2W in various mouse tissues 
shown earlier (Fig 6C). No Ube2W species existed corresponding to Met1 (Fig 
7C). While these data indicate that both start sites can be used to generate 
Ube2W protein, the downstream start site appears to be the preferred initiation 
site in normal murine tissues and MEFs.  
 
Ube2W KO mice are susceptible to postnatal lethality and growth 
retardation 
Ube2W heterozygous mice (HET) were crossed to obtain Ube2W KO 
mice. Although Ube2W KO mice appear to undergo normal prenatal 
development, they are susceptible to death near or soon after birth. Whereas 
only 1 of 13 (7.7%) WT and 3 of 38 (7.9%) HET pups died at postnatal day 0 (P0), 
6 of 18 (33.3%) KO pups died at P0. Ube2W KO mice showed continued lethality 
until postnatal day 2 (P2): 0 of 39 (0%) WT pups, 1 of 38 (2.6%) HET pups and 4 
of 18 (22.2%) KO pups died on postnatal days 1 or 2. After P2, Ube2W KO mice 
displayed no further increased lethality: 1 of 13 (7.7%) WT pups, 1 of 38 (2.6%) 
HET pups and 1/18 (5.5%) KO pups died between P2 and 16 weeks of age. To 
assess when susceptibility to early lethality first appears in KO mice, embryonic 
day 18.5 (E18.5) embryos were extracted and examined: 0 of 9 (0%) WT 
embryos, 1 of 16 (6.2%) HET embryos and 1 of 10 (10%) KO embryos were 
nonviable, indicated by the absence of a heart beat (Fig 8A and B). In total, 55.6% 
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of Ube2W KO mice died before P2, revealing an important role for Ube2W in 
early postnatal survival.  
Histopathologic examination of major organs did not detect any significant 
morphologic differences in KO embryos/pups at E16.5, E18.5 and P0 at the 
microscopic level (Fig 8C). Furthermore, whole-mount Ube2W KO mice showed 
no evidence of increased apoptosis, measured by terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) staining at E16.5, E18.5 and P0 
(data not shown). 
Two reported Ube2W substrates are the neurodegenerative disease 
proteins Ataxin-3 and Tau (25, 56), suggesting a potentially important role for 
Ube2W in brain. To eliminate Ube2W expression selectively in the Central 
Nervous System (CNS), we crossed Ube2W Flox/Flox mice with Nestin 
promoter-driven, Cre recombinase-expressing mice. Analysis of these mice 
showed that Ube2W expression was eliminated in the brain and spinal cord but 
persisted in other organs. Ube2W Nestin-KO mice did not show postnatal 
lethality, and were recovered at the expected Mendelian ratios (19 of 35 
genotyped mice were KO, in line with the breeding strategy prediction of 50%). 
Thus, the postnatal lethality of Ube2W KO mice is not due to overt brain 
dysfunction.  
While the organismal morphology of Ube2W KO mice appears normal at 
birth, Ube2W KO pups weighed significantly less than WT and HET littermates 
overtime. This decreased body weight was maintained throughout postnatal 
development in male and female mice. Adult Ube2W KO mice remained 
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approximately 20% smaller than WT mice (Fig 8E and F). Most organs showed a 
proportionate decrease in size, commensurate with the overall reduced body size. 
The testis and thymus (Fig 8D), however, showed a disproportionate weight 
decrease of approximately 50%, indicating a potential important function for 
Ube2W in these organs. 
 
Ube2W deficient mice display altered epidermal differentiation 
One possible cause of early postnatal lethality is a defect in the protective 
barrier provided by skin. Indeed, histological analysis of P0 pups revealed 
striking alterations in the epidermis of Ube2W KO mice, except in the scalp. 
Normal epidermis contains 4 cellular compartments, which include a single layer 
of undifferentiated basal cells that give rise to several layers each of spinous 
cells, granular cells, and anucleate cornified cells (Fig 9A). The most severe 
phenotype was observed in dorsal skin: KO mice showed a loss of granules 
normally found in the granular cell layer and more distinct cell borders compared 
to WT epidermis (Fig 9A). Further, immunostaining revealed a reduction and 
altered distribution of loricrin, a granular cell marker that is incorporated into 
terminally differentiated, cornified cell envelopes in the cornified cell layer. 
Compared to its cytoplasmic distribution pattern in the stratum granulosum of WT 
skin, loricrin in KO skin is localized to the periphery of epidermal cells in the 
upper epidermis (Fig 9B). Cells expressing Keratin 1 (K1) and Keratin 10 (K10) 
normally exist in the stratum granulosum and spinosum, but were detected only 
in the lower suprabasal cell layer in KO mice (Fig 9C). In contrast, 
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immunostaining for the basal cell marker K5 was similar in KO and WT mice (Fig 
9D). This abnormal skin phenotype was observed in 4 out of 6 P0 KO mice 
analyzed. Collectively, these data establish that the loss of Ube2W can result in 
severely altered epidermal differentiation. 
 
Ube2W KO mice display neutrophilia and increased G-CSF recruitment 
Due to high Ube2W expression in the thymus and a disproportionate 
decrease in thymus weight in Ube2W KO mice, we sought to determine whether 
Ube2W regulates development of the immune system. Immune cells were 
extracted from major immune organs including thymus, spleen, liver, lymph 
nodes (axillary, brachial, and inguinal pooled) and blood, and analyzed by flow 
cytometry according to quantification of cell types using established cell surface 
markers. CD45+, CD11b+, CD11C-, Ly6C+, Ly6G+, neutrophils comprised 5.55% 
± 1.95% of total cells of the blood in Ube2W KO mice, which was significantly 
compared to that of WT mice (0.68% ±0.09%) (Fig 10A-C). In 6 of 10 KO mice 
tested, neutrophils were also more abundant in lymph nodes. Other immune cell 
types including CD4+ T cells, CD8+ T cells, B cells, monocytes and dendritic cells 
were not significantly altered in blood or other immune organs of Ube2W KO 
mice (data not shown).  
The increased numbers of neutrophils in blood of Ube2W KO mice led us 
to hypothesize greater chemokine-driven mobilization from bone marrow. Indeed, 
Ube2W KO mice showed a significant increase in serum G-CSF levels but lower 
serum GM-CSF levels, suggesting the increase in G-CSF in Ube2W KO mice 
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results in aberrant neutrophil recruitment from the bone marrow (Fig 10D and E). 
To quantify neutrophil trafficking in WT and Ube2W KO mice, peritonitis was 
induced by intraperitoneal injection of thioglycollate. After 4 hours, neutrophils 
were recovered by peritoneal lavage and analyzed by flow-cytometry. While 
there was no statistically significant difference in total neutrophils recruited, there 
was a trend toward an increased population of immature neutrophils in peritoneal 
lavage, identified by lower Ly6C expression (p=0.09), suggesting a premature 
exit of these cells from the bone marrow in Ube2W KO mice (Figure 10F).  
 
Ube2W KO male show decreased fertility accompanied by testicular 
vacuolation 
Because Ube2W is expressed robustly in the testis and testis weight is 
disproportionately decreased in Ube2W KO mice, we suspected an important 
function for Ube2W in testis. Consistent with this hypothesis, in breeding pairs of 
Ube2W KO males and WT females, nearly half of Ube2W KO males failed to 
generate litters, suggesting infertility. To assess possible changes in testicular 
cellular integrity and spermatogenesis, we performed histochemical analyses of 
testes and epididymides from 16-week-old WT and Ube2W KO mice.  
Whereas testes from WT mice were histologically normal (Figure 11A), 
showing cells corresponding to each phase of germ cell maturation from 
spermatogonia to spermatozoa, testes of KO mice displayed variable 
degeneration and atrophy of seminiferous tubules, ranging from mild and focal 
vacuolation of the basal layer of spermatogonia (Figure 11B) to marked decrease 
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in tubule diameter with diffuse tubular atrophy, vacuolation, and the absence of 
spermatocytes and spermatids (Figure 11C). Compared to WT epididymides that 
typically showed abundant mature spermatozoa (Figure 11D), KO epididymides 
showed variable sperm levels ranging from a normal amount of mature 
spermatozoa corresponding to a mildly vacuolated testis (Figure 6E) to a 
complete absence of mature spermatozoa corresponding to a severely 
vacuolated testis (Figure 11F). The epithelium and interstitial Leydig cells of 
Ube2W KO mice appeared normal. Ovaries from 16-week-old female Ube2W KO 
and WT mice showed no overt difference in size and structure (data not shown). 
 
Ube2W KO mice testes show accumulation of disordered proteins 
Because of the potential importance of Ube2W in the male reproductive 
system, we analyzed and compared protein expression profiles in pre-
symptomatic 4-week-old WT versus Ube2W KO testis, using TMT-labeled LC-
MS/MS to compare expression profiles. At 4 weeks, mice testes are structurally 
and functionally mature but have not yet developed the distinct vacuolation 
pathology of Ube2W KO mice. We analyzed three technical replicates each from 
WT and Ube2W KO testis. Among 4,544 proteins identified in testis with at least 
two peptide spectrum matches (PSMs), 135 proteins showed more than a 1.5-
fold increase in Ube2W KO testis. This group, which represents potential Ube2W 
substrates, comprised the target group for subsequent bioinformatics analysis. 
Bioinformatic analysis of protein disorder was based on the percent of disordered 
amino acids in each protein (percent disorder) identified by IUPred (166). 
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Compared to the reference group (4,309 identified proteins excluding the target 
group), the target group of enriched proteins shows a significantly skewed 
distribution of disorder (p=0.02 by Kolmogorov-Smirnov test), with higher disorder 
percentages being more prevalent in the target group (Fig 12A). A similar, 
negative-skewed distribution of protein disorder is observed when using 
DisEMBL prediction of COILS (Fig 12B) (167), further suggesting an 
accumulation of relatively disordered proteins in Ube2W KO testis. These results 
are consistent with the in vitro evidence that Ube2W preferentially ubiquitinates 
disordered substrates (68). This preference of Ube2W, however, is believed to 
be most critical for disorder at the N-terminus. Accordingly, we also analyzed the 
prevalence of continuous length disorder (CLD) in the target group, which can 
provide more detail regarding the organization of disorder than percent disorder. 
Using a CLD stretch of disordered amino acids of at least 30 aa as the threshold 
(168, 169), we examined the existence of IUPred-based CLD in both full length 
proteins (100% amino acids) and the N-terminus of proteins (first 2.5%, 5% and 
10% amino acids). Consistently, the target group showed a greater percentage of 
proteins with a CLD in the N-terminus (Fig 12C). This feature is also more 
prevalent in the target group of proteins, when using the DisEMBL prediction of 
COILS (Fig 12D).  
Among proteins in the target group, protamine-2 is an attractive candidate 
because its levels were increased nearly four-fold in Ube2W KO testis via 
proteomic analysis and because it has highly disordered characteristics, 
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predicted by both IUPred and DisEMBL. Indeed, by Western blot protamine-2 is 
significantly elevated in 4 week-old testis from Ube2W KO mice (Fig 12E and F).  
 
Ube2W deficiency does not alter cell tolerability to DNA interstrand 
crosslinking 
DNA damage repair pathways are critical to testicular function. Because 
FANCD2 can be monoubiquitinated by Ube2W in vitro and monoubiquitinated 
FANCD2 is a critical component of the Fanconi Anemia (FA) pathway regulating 
DNA repair after interstrand crosslinking, we investigated the susceptibility of 
Ube2W KO MEFs to DNA interstrand crosslinking.  When DNA crosslinking was 
introduced by Mitomycin C (MMC) treatment for 24hrs, Ube2W KO MEFs failed 
to show a significant increase in MMC-induced toxicity (Figure 13A). Earlier (Fig 
6) we showed that Ube2W is a cytoplasmic protein in MEFs, suggesting that 
Ube2W would not be available to mono-ubiquitinate FANCD2 in the nucleus. 
Accordingly, we tested whether Ube2W translocates to the nucleus in response 
to DNA damage. After MMC or UV treatment, Ube2W remained in the cytoplasm 
without translocation to the nucleus (Figure 13B). Despite Ube2W’s capacity to 
mono-ubiquitinate FANCD2 in vitro, its ability to do so in vivo remains uncertain.  
 
Loss of Ube2W does not impair the cellular response to various cytotoxic 
stressors 
Increased early postnatal stress of various types, including oxidative and 
endoplasmic reticulum (ER) stress, contributes to diseases of the newborn (170–
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172). Because ubiquitin signaling has been implicated in the cellular response to 
such stresses, we sought to determine whether the loss of Ube2W renders cells 
prone to various cell stressors. Skin-derived fibroblasts harvested from Ube2W 
KO and control heterozygous mouse tails were treated with stressors targeting 
various cellular pathways: tunicamycin and thapsigargin (ER stress), H2O2 (ROS 
stress), MMS (DNA damage stress), cadmium (heavy metal stress), glucose 
deprivation (nutrient stress), and NH4Cl (autophagy stress). A median lethal dose 
(LD50) was measured for each stressor and the value compared between 
Ube2W KO and control cells. Ube2W KO fibroblasts did not show altered 
susceptibility to any stressor tested. We conclude that, at least in fibroblasts, 
Ube2W is not essential to the cellular response to common cellular stressors 
(Figure 14).  
 
2.5 DISCUSSION 
Protein ubiquitination is critically important to diverse aspects of many 
different cellular pathways. The enzyme cascade mediating ubiquitination 
achieves the necessary rich diversity of substrate ubiquitination through pairing a 
limited pool of E2s  (38 in humans) with a wide range of E3s (estimated at more 
than 1000 in humans) (173). Each E2 engages multiple E3 partners to carry out 
diverse substrate-specific ubiquitination events, thus the loss of any given E2 can 
have profound deleterious effects on an organism. In mice, for example, deletion 
of Ube2I, Ube2L3, Ube2N or BIRC6 results in lethality in utero (174–178); while 
deletion of Ube2A, Ube2B or Ube2D2a causes infertility (179, 180). Our results in 
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Ube2W KO mice establish that Ube2W, an atypical E2 implicated in N-terminal 
ubiquitination, contributes to vital ubiquitin pathways involving multiple organ 
systems. 
Ube2W is the only known mammalian E2 that ubiquitinates substrates on 
their N-termini rather than on internal lysine residues (56, 67). Ube2W may 
preferentially target substrates with intrinsically unfolded amino-termini (68), but 
its expression and function in vivo are poorly understood. Our data reveal 
widespread Ube2W expression in the mouse, particularly of Ube2W isoform 1, 
with protein translation beginning at the second predicted Kozak sequence. 
Compared to the predicted Ube2W protein initiated from the first Kozak 
sequence, this smaller Ube2W species lacks 29 amino acids that include a 
predicted nuclear-localization signal. Thus, it is perhaps not surprising that the 
major expressed isoform of Ube2W is a cytoplasmic protein in mouse embryonic 
fibroblasts and in transfected cells (Fig 6D). When mouse tissue lysates are 
separated by SDS-PAGE, Ube2W exists as a single species of approximately 16 
kDa, suggesting conservation of isoform expression across different tissues.  
In contrast to the early embryonic lethality of several other E2s, the early 
postnatal lethality of Ube2W KO mice is not fully penetrant: 60% of Ube2W KO 
mice died between E18.5 and P2 in the C57Bl/6 background. The susceptibility 
to early lethality indicates an important, but not essential, early postnatal function 
for Ube2W. The incomplete penetrance of this phenotype could reflect 
compensatory up-regulation of other E2s or E3s serving similar functions. We 
have measured levels of known Ube2W-interacting E3 ligases, including CHIP, 
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BRCA1 and FANCD2 in MEFs, none of which is altered in Ube2W KO cells (data 
not shown). Conceivably other as yet unknown E2/E3 pairs compensate for 
Ube2W deficiency, or ubiquitination of the amino-termini of specific substrates 
may be redundant with additional posttranslational signaling events. Our data 
further suggest that the loss of Ube2W does not cause a dramatic change in 
stress-induced cell effects, implying that other effects beyond basic cellular 
stress pathways are involved in this early postnatal lethality.  
The altered epidermal differentiation pattern observed in P0 KO mice 
suggests delayed or impaired maturation of stratum granulosum and spinosum. 
The sequential differentiation of epidermis is essential for post-natal survival. The 
loss of keratohyalin granules and altered Loricrin immunostaining in Ube2W KO 
P0 mice suggest a defect in barrier function, which can result in early postnatal 
lethality due to excessive water loss (reviewed in 37, 38). In Ube2W KO mice, 
the 60% postnatal lethality we observe is a similar percentage to that of the 
altered skin phenotype, suggesting a potential link between the epidermal 
differentiation defect and early postnatal lethality. Further studies are needed to 
establish whether Ube2W KO mice are susceptible to dehydration concomitant 
with these observed skin abnormalities. Further analysis of the pathogenesis of 
skin defects in Ube2W KO mice also may shed light on specific ubiquitin-
dependent pathways critical to normal epidermal differentiation.  
The neutrophilia observed in Ube2W KO mice could result from different 
scenarios. We favor the view that sustained neutrophilia in adult Ube2W KO mice 
is secondary to increased expression of neutrophil-mobilizing cytokines since G-
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CSF levels were higher in the serum of Ube2W KO mice. Increased G-CSF 
together with neutrophilia can be observed in systemic bacterial infections, but 
the fact that this phenotype was consistently observed at different stages of 
development in mice kept in pathogen-free conditions argues against this 
possible explanation. Moreover, recruitment of neutrophils is intact in Ube2W KO 
mice, arguing against an intrinsic neutrophil defect and further supporting the 
view that neutrophilia is a secondary event reflecting increased serum G-CSF. G-
CSF is primarily degraded by neutrophil elastases, but there is no published 
literature suggesting ubiquitin-associated degradation of G-CSF. G-CSF 
synthesis occurs in different cell populations, including monocytes, endothelium 
and keratinocytes, so perhaps Ube2W plays a regulatory role in G-CSF secreting 
cells to govern circulating blood neutrophils. The decreased GM-CSF level in 
Ube2W KO mice is probably secondary to neutrophilia, as the increased number 
of circulating neutrophils in Ube2W KO mice likely would capture more GM-CSF 
through their GM-CSF receptors, resulting in the decreased levels seen in 
Ube2W KO mice. 
A key question regarding Ube2W is: what are its natural target substrates? 
The testis, which appears vulnerable to the loss of Ube2W based on the 
observed vacuolation in seminiferous tubules and high rate of male infertility, 
provided us an opportunity to begin addressing this question. Specifically, we 
examined changes in the testis proteome in the absence of Ube2W. In Ube2W 
KO testis, bioinformatic analysis revealed an accumulation of proteins with 
increased disorder, consistent with the recent view that Ube2W may 
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preferentially target substrates with disordered N-termini (68). The extreme N-
termini (approximately the first five amino acids) may be the key determinant for 
substrate recognition by Ube2W (21), but most proteins in the mouse proteome 
(70-80%) are predicted to show disorder in the first five amino acids, based on 
DisEMBL analysis (with COILS, Hotloops and REM465). Accordingly, we were 
unable to discern differences linked to the extreme N-termini. By expanding our 
analysis of N-termini to first 2.5%, 5% and 10% of proteins, however, we noted 
that proteins enriched in Ube2W KO testis are more likely to contain stretches of 
disordered amino acids. This preferential accumulation of disordered proteins in 
Ube2W KO testis is consistent with the view that Ube2W preferentially 
ubiquitinates disordered substrates and that such ubiquitination serves as a 
degradation signal. More work is required, however, to establish that Ube2W-
mediated ubiquitination favors disordered proteins and regulates their steady 
state levels. The testicular proteome offers numerous candidate proteins for such 
future analysis, including protamine-2, an intrinsically disordered testicular 
protein that we confirmed was increased in the absence of Ube2W. 
Ubiquitin pathways are known to be important to the maintenance of 
testicular structure and function. Knockout models of many E3 ligases including 
RNF8 have shown similar testicular vacuolation defects and infertility(183–185). 
Moreover, DNA damage pathways are implicated in spermatogenesis: RNF8, 
FANCD2 and BRCA1 all participate in DNA damage pathways and can interact 
with Ube2W in vitro. Ube2W deficient fibroblasts, however, failed to show a 
significant difference in the cellular response to a form of DNA damage: 
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mitomycin C induced DNA crosslinking. This result is consistent with a recent 
study in which Ube2W was shown to efficiently mono-ubiquitinate FANCD2 yet a 
Ube2W-deficient chicken cell line did not show increased sensitivity to mitomycin 
C-induced lethality (22). Although Ube2W is capable of ubiquitinating FANCD2, it 
may be functionally redundant in the cellular response to DNA damage response. 
Moreover, when cells were stressed with mitomycin C, Ube2W failed to be 
recruited into the nucleus, making it physically difficult for Ube2W to participate 
directly in DNA damage repair. Taken together, these results lead us to believe 
that testicular vacuolation in Ube2W KO mice is not likely to be due to a defective 
DNA damage response. 
In summary, utilizing a novel Ube2W KO mouse model we have 
established that Ube2W is a widely expressed, predominantly cytoplasmic E2 
that plays an important, nonessential role in several divergent organ systems. 
Our data indicate that Ube2W functions as a significant factor in mouse postnatal 
survival as well as in skin differentiation, G-CSF related immune response and 
male fertility. We stress that we closely examined only these three divergent 
organ systems based on clues provided by the Ube2W KO mice. Accordingly, we 
have not ruled out Ube2W’s involvement in other organ systems. Moreover, all 
studies were performed on a pure C57Bl/6 genetic background and led to 
incompletely penetrant phenotypes. Further analysis of Ube2W deficiency in 
different inbred murine strains could exacerbate or lessen these phenotypes, and 
thereby provide additional genetic clues to the in vivo role of Ube2W. Finally, the 
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availability of Ube2W KO mice should facilitate the identification of key 
physiological substrates for this unusual E2 in affected tissues. 
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2.6 FIGURE LEGENDS 
FIGURE 6. Generation of Ube2W KO mouse and expression of Ube2W.  
A. Targeting strategy of Ube2W KO mouse: targeting vector is shown in (i), Flp-
FRT recombination results in deletion of lacZ and Neo gene shown in (ii), further 
Cre-loxP recombination results in deletion of Ube2W exon 3 shown in (iii), this 
frameshift mutation causes loss of Ube2W expression. B. Gel electrophoresis of 
PCR amplification products from Ube2W KO and WT mice. WT size: 925bp, KO 
size: 394bp. C. Western blot of tissue lysates from Ube2W KO and WT mice, 
probed with anti-Ube2W and anti-GAPDH antibody as loading control. (30ug 
protein loaded per lane.) D. Western blot of cell fractionation lysates from KO and 
WT mouse embryonic fibroblasts (MEFs) probed with anti-Ube2W, Hsp-90 
(cytosolic), Gai-2 (membrane-bound) and Histone H3 (nuclear) antibodies. (15ug 
protein loaded per lane.) E. Immunofluorescence (anti-myc, red; DAPI, blue) on 
HEK293 cells transiently transfected with myc tagged, human Ube2W equivalent 
to murine isoform 1 (Scale bar = 10 µm) 
 
FIGURE 7. Ube2W isoform 1 beginning at Met30 is the predominant Ube2W 
species in mouse.  
A. Schematic diagram of predicted murine Ube2W isoforms. Colored boxes 
indicate Ube2W coding exons. Common protein sequences across isoforms are 
represented in the same colors. Coding sequence length and predicted 
molecular weight are listed. Arrows indicate primers used in (B). Pr. Pair 1: For 
and Rev-1; Pr. Pair 2: For and Rev-2; Pr. Pair 3: For and Rev-3. B. PCR 
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amplification of Ube2W first strand cDNA from KO and WT MEFs. Expected 
band sizes are listed in table; numbers in parentheses indicate predicted bands 
that were not observed. Arrowheads and arrows denote bands corresponding to 
KO and WT isoform 1, respectively. C. Diagram on right shows two possible 
Ube2W protein sequences beginning at different potential start Methionines 
(Met1 and Met 30). Green color indicates peptide sequence unique to Met1. 
Western blot of HEK 293 cells overexpressing Ube2W Met1 or Ube2W Met30 
(0.2ug total protein loaded), run adjacent to MEF lysates from WT, heterozygous 
and KO mice (20ug total protein loaded), probed with anti-Ube2W antibody.  
 
FIGURE 8. Ube2W KO mice are susceptible to early postnatal lethality and show 
retarded growth. 
A. Survival curves for WT (black, n=13), heterozygous (blue, n=38) and 
homozygous Ube2W KO mice (red, n=18). Ube2W KO mice display early 
lethality before postnatal day 2. Data at P0 represents number of both mice that 
either died in utero or were dead immediately upon birth. Heterozygous mice 
show normal survival curves. B. Representative bar graph of Ube2W KO mice 
lethality at embryonic day 18.5, postnatal day 0, postnatal day 2 and 16 weeks; 
shown as percentage. C. Representative images of H&E stained whole embryo, 
sagittal section (E18.5). Ube2W KO embryos show no apparent overt histological 
difference in internal organs. D. Proportionate organ weight decrease in Ube2W 
KO mice compared to decrease in whole body weight. Error bars indicate SEM 
(n=8). E. Representative growth curve (means and ranges) of female WT (circles, 
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n=11), heterozygous (squares, n=14) and homozygous Ube2W KO (triangles, 
n=10) mice. F. Representative growth curve (means and ranges) of male WT 
(circles, n=9), heterozygous (squares, n=11) and homozygous Ube2W KO 
(triangles, n=9) mice. 
 
FIGURE 9. Defective skin terminal differentiation in Ube2W KO mice.  
Images of dorsal skin from P0 WT (left two columns) and Ube2W KO (right two 
columns) mice. Column 2 and 4 are higher magnification of inserts in column 1 
and 3. Dashed lines indicate basal cell layer. A. Hematoxylin and Eosin (H&E) 
staining of dorsal skin. Wild-type epidermis contains basal (b), spinous (s), 
granular (g), and cornified (c) cell layers.  Note absence of keratohyalin granules 
in mutant epidermis.  B. Restricted expression of granular cell marker Loricrin to 
the cell periphery in Ube2W KO skin, compared with cytoplasmic expression in 
WT epidermis. C and D. Expression of spinous cell markers Keratin 1 (K1) and 
Keratin 10 (K10) in 1-2 layers of suprabasal cells in Ube2W KO mice skin, 
compared with expression in WT spinous layers that persists in granular cell 
layers. E. Immunostaining of basal cell marker Keratin 5 (K5) shows a similar 
pattern in wild-type and Ube2W KO skin. Scale bar=50 µm, insert scale bar=20 
µm. 
 
FIGURE 10. Ube2W KO mice show neutrophilia and increased G-CSF signaling.  
A and B. Representative flow-cytometry sorting of neutrophils in WT (A) and 
Ube2W KO (B) mouse blood. N= neutrophils (CD11b+Ly6G+Ly6C+). C. 
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Percentage of neutrophils in all CD11b+CD45+ blood cells from WT (black) and 
Ube2W KO (grey) mice. n=10. D and E. Serum levels of G-CSF (D) and GM-CSF 
(E), measured by bead-based multiplex analysis. n=6. F. Percentage of immature 
neutrophils (CD11b+Ly6G+Ly6Clow) in all CD11b+CD45+ cells from intraperitoneal 
lavage 4 hours after thioglycollate injection. n=6. All graphs indicate means; error 
bars denote SEM. *, P < 0.05. 
 
FIGURE 11. Testicular vacuolation in Ube2W KO mice.  
A-C. Images of H&E stained seminiferous tubules from 16-week-old WT (A) and 
Ube2W KO (B and C) mice. Testes from KO mice show variable vacuolations 
within seminiferous tubules, ranging from focal vacuolation of spermatogonia and 
spermatocytes (B, arrows) to diffuse vacuolation and loss of spermatocytes with 
marked atrophy of seminiferous tubules (C). D-F. Images of H&E stained 
epididymis (D-F) from the WT (D) and Ube2W KO (E and F) mice shown in A-C. 
Epididymi from Ube2W KO mice showed no histological abnormalities but a 
variable reduction in mature sperm (E-F). Bars= 50 µm (A-C); 100µm (D-F).  
 
FIGURE 12. Testicular proteomic analysis shows a preferential accumulation of 
disordered proteins in Ube2W KO mice.  
A. Distribution of full length proteins according to IUPRED calculation of percent 
disorder (PD). p=0.02 (KS test). In panels A-D, the reference set (black bars) 
includes all identified testicular proteins minus the target set (gray bars) of 
proteins whose levels are increased >1.5 fold in Ube2W KO mouse testis. B. 
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Distribution of full length proteins according to DisEMBL-COILS calculation of 
percent disorder (PD). P=0.004 (KS test). C. Percentage of proteins containing 
continuous length disorder (CLD) of at least 30 amino acids, according to 
IUPRED, based on analysis of the amino-terminal first 2.5%, 5% or 10% of the 
protein or the full protein sequence. D. Percentage of proteins containing CLDs 
of at least 30 amino acids, according to DisEMBL-COILS, based on analysis of 
the amino-terminal first 2.5%, 5% or 10% of the protein or the full protein 
sequence. E. Western blot confirmation of increased levels for a top identified 
target protein, Protamine-2; GAPDH as loading control. (30ug total protein 
loaded per lane.) F. Quantification of Western blot in panel E. p=0.002, n=2. 
 
FIGURE 13. Ube2W deficiency does not alter cell tolerability to DNA interstrand 
crosslinking.  
A. MEF survival after 24hour treatment with increasing concentrations of 
mitomycin C (MMC). B. Western Blot of different cell fractionation lysates from 
WT and Ube2W KO mouse embryonic fibroblasts (MEFs) after treatment with 
MMC or UV radiation, blotted with anti-Ube2W, Hsp-90 (cytosolic) and Histone 
H3 (nuclear) antibodies. (15ug total protein loaded per lane.) 
 
FIGURE 14. Ube2W KO skin-derived fibroblasts show no difference in response 
to various cell stressors.  
A. Representative cell survival at various tunicamycin concentrations; the figure 
shows results for fibroblasts from four individual Ube2W KO and heterozygous 
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(HET) mice. B. Compilation of LD50 results from experiments as in panel A; each 
symbol representing a different donor mice. C-H. Compilation of LD50 results for 
treatment with thapsigargin (C), H2O2 (D), MMS (E), cadmium (F), glucose 
deprivation (G), and NH4Cl (H). All graphs show means +/- SEM. *, P < 0.05. n=4 
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Chapter Three: Ube2W regulates mutant Huntingtin 
solubility 

3.1 ABSTRACT 
Huntington’s Disease (HD) is caused by polyglutamine (polyQ) expansion 
in the HD disease protein, huntingtin (Htt). PolyQ expansion leads to Htt 
misfolding and accumulation as inclusion bodies within neurons. Ube2W is the 
only ubiquitin conjugating enzyme (E2) that ubiquitinates substrates at the 
disordered amino-termini. Htt is known to have an intrinsically disordered amino 
terminus. In this study, I tested whether Ube2W is capable of regulating Htt. To 
investigate this potential non-canonical ubiquitination of Htt, I performed studies 
in immortalized cells, primary neurons and a knock-in (KI) mouse model of HD to 
study the effect of Ube2W deficiency on Htt levels, inclusion formation and 
neurotoxicity.  In cultured cells, functional deficiency of Ube2W markedly 
decreases inclusion formation and increases the level of soluble monomers, 
while reducing Htt cytotoxicity. Consistent with this result, the absence of Ube2W 
in HdhQ200 KI mice significantly increases levels of HttQ200 soluble monomers 
without altering Htt inclusion and expression of striatal markers. This study sheds 
light on the potential function of non-canonical N-terminal ubiquitination in an 
important neurodegenerative disease and supports the view that post-
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translational modification at or near the N-terminus of Htt modulates Htt solubility 
and aggregation formation.  
 
 
3.2 INTRODUCTION 
Accumulation of ubiquitinated proteins is commonly observed in 
neurodegenerative diseases, shared as a pathological hallmark shared by many 
neurodegenerative diseases including Huntington’s disease (HD). HD is the most 
common polyglutamine (polyQ) disease. The CAG repeat expansion encodes a 
polyQ stretch in the disease protein huntingtin (htt). When the polyQ length 
exceeds a threshold of ~40 glutamines, it becomes pathogenic(120). HD patients 
typically develop various clinical signs and symptoms including involuntary 
movements such as chorea and dystonia, neuropsychiatric symptoms and 
cognitive deficits. Histopathologically, HD displays a progressive spreading 
pattern: the brain region first affected is the striatum, particularly the loss of 
medium spiny neurons that express dopamine D2 receptors, DARPP-32 and the 
neurotransmitter enkephalin(124–127).   
In HD, the polyQ stretch resides very near the N-terminus of htt and 
contributes to the disorderness and misfolding of htt. Expanded Htt becomes 
insoluble and forms inclusion bodies in neuronal nuclei, perinuclear regions and 
neurites(131–133). Immunohistochemical studies revealed that these inclusion 
bodies contain N-terminal regions of htt, ubiquitin, proteasomal components and 
numerous other proteins(132). The discovery of ubiquitin and proteasomal 
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subunits in HD inclusion bodies supports the importance of ubiquitin-dependent 
pathways in HD pathogenesis. However, the exact roles of ubiquitination in HD 
are not fully understood. Studies have shown that numerous components of 
ubiquitin-dependent systems can contribute to and alter htt degradation, 
aggregation and cytotoxicity. K11, K48 and K63-linked polyubiquitin-modified 
proteins have been identified in HD inclusion bodies, suggesting a regulatory role 
of either the proteasome or autophagy systems in htt inclusion formation. 
Furthermore, ubiquitin-like molecules such as SUMO have proved to be 
important regulators in htt aggregation(144, 145).  
Ubiquitin (Ub) conjugation involves a sequential action of enzymes to 
target ubiquitin to substrates: Ub-activating enzyme (E1), Ub conjugating enzyme 
(E2) and Ub ligase (E3). Taking into consideration different Ub-chain lengths, 
linkages and substrate attachment sites, dramatically different kinds of 
ubiquitination can occur. The variety of ubiquitination pattern is mainly achieved 
by different combinations of E2/E3 pairs. Recently, Ube2W was identified as the 
only E2 that can recognize disordered N-termini of proteins and initiate 
ubiquitination at the α-amino group(56, 67, 68). Ube2W can function with various 
ubiquitin ligases including the C terminus of Hsc-70-interacting protein (CHIP) 
and the BRCA1/BARD1 complex to mono-ubiquitinate select substrates at their 
amino-termini(25, 56, 68–70). 
Given the highly disordered nature of the N-terminal domain of Htt, I 
predict it to be a strong candidate target for Ube2W. Currently the function of Htt 
N-terminal ubiquitination is unknown. In this chapter, I utilize different model 
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systems to study the effect of Ube2W deficiency to Htt protein levels, aggregation 
and neurotoxicity.  
 
 
3.3 EXPERIMENTAL PROCEDURES 
Animals - Ube2W germline KO mice were generated as described in 
chapter 2. Ube2W neuronal KO mice were generated by crossing Ube2W 
Flox/Flox mice (described in chapter 2) with Nestin promoter driven Cre 
transgenic mice from Jackson Laboratory (B6.Cg-Tg(Nes-cre)1kln/J), in which 
Cre is expressed in central nervous systems. All mice in this study were 
maintained on a pure C57BL/6 genetic background, housed in cages with a 
maximum number of five animals and maintained in a standard 12-hour light/dark 
cycle with food and water ad libitum. Genotyping was performed using DNA 
isolated from tail biopsy at the time of weaning, otherwise indicated. Genotype 
was determined by PCR amplification of a fragment of gene-of-interest. To model 
Huntington’s disease, I utilized the heterozygous HD-KI Q200 (HdhQ200) mouse 
model expressing murine Htt with ~200 CAG repeats(186, 187). Mice were 
euthanized at specific ages, anesthetized with ketamine/xylazine, and perfused 
transcardially with phosphate-buffered saline. 
PCR primers - For Ube2W KO genotyping: 
5’AAAGGAAGAGCCCAGTATGGACCCT3’ and 
5’AGAGTCCCTGCAGCTATTAC3’;  
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Cre genotyping: 5’GTCCAATTTACTGACCGTACACC3’, 
5’GTTATTCGGATCATCAGCTACACC3’, 
5’CTAGGCCACAGAATTGAAAGATCT3’ and 
5’GTAGGTGGAAATTCTAGCATCATCC; 
Flox genotyping: 5’AAAGGAAGAGCCCAGTATGGACCCT3’ and 
5’TGTGTTTTGTTTTAATCTTTCTGGCC3’; 
Hdh genotyping: 5’CCCATTCATTGCCTTGCTG3’ and 
5’GCGGCTGAGGGGGTTGA3’; 
Hdh qRT-PCR: 5’TTGTGTTAGATGGTGCCGAT3’ and 
5’GTTGAAGGGCCAGAGAAGAG3’. 
Transfection and immunofluorescence imaging - Human embryonic kidney 
293 (HEK293) cells were cultured in DMEM, supplemented with 10% FBS, 
100U/ml penicillin/streptomycin. Transfections were carried out with 
lipofectamine 2000 (Invitrogen) as described previously(187). GFP fluorescence 
was visualized by Olympus IX-71 fluorescence microscope. 
Plasmids - pcDNA3.1-Httex1Q103-GFP and pGW1-mApple has been 
reported previously(187–189); pCMV6-Ube2W plasmid was from Origene 
(RC204985), C91A and W144E mutations were introduced using Quikchange 
Lightning Site-Directed Mutagenesis (#210518, Agilent Technologies); pGW1
Httex1-(Q17 or Q72)-EGFP were kindly provided by Dr. Steven Finkbeiner(190). 
Western blotting - Protein lysates from different cells were generated by 
lysis in radioimmunoprecipitation assay (RIPA) buffer containing protease 
inhibitors (Complete-mini; Roche Diagnostics, Indianapolis, IN), followed by 
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sonication and centrifugation. The supernatants were collected. For transfection 
experiments, transfected cells were lysed with 0.5% Triton X-100 lysis buffer 
containing 150 mM NaCl, 20 mM Tris/HCl, pH 8.0, 5 mM EDTA and complete 
Mini Protease Inhibitor tablets. Insoluble material was further lysed with 2X 
Laemmli buffer. Total protein concentration was determined using the BCA 
method (Pierce, Rockford, IL) and then stored at −80 °C. Proteins were resolved 
in sodium dodecyl sulfate–polyacrylamide gel electrophoresis gels, and 
corresponding polyvinylidene difluoride membranes were incubated overnight at 
4 °C with primary antibodies: rabbit anti-Ube2W (1:1,000; 15920-1-AP; Protein 
Tech Group), mouse anti-GAPDH (1:10,000; MAB374; EMD Millipore), rabbit 
anti- α tubulin (1:10,000; #2144; Cell Signaling Technology), rabbit anti-GFP 
(1:1,000; sc-8334; Santa Cruz Biotechnology), mouse anti-polyglutamine 
(1:2,000; MAB1574; EMD Millipore), mouse anti-Huntingtin (1:250, MAB2166, 
EMD Millipore), rabbit anti-Hsp40 (1:1,000; #4868, Cell Signaling Technology), 
rabbit anti-Hsp60 (1:1,000; ab46798, abcam), mouse anti-Hsp70 (1:1,000; SPA-
810, Enzo Life Sciences) and mouse anti-Hsp90 (1:1,000; SAP-830, Enzo Life 
Sciences). Bound primary antibodies were visualized by incubation with a 
peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody (1:10,000; 
Jackson Immuno Research Laboratories, West Grove, PA) followed by treatment 
with the ECL-plus reagent (Western Lighting; PerkinElmer, Waltham, MA) and 
exposure to autoradiography films.  
35S-Methionine labeling and immunoprecipitation - At 24h after 
transfection, cells were labeled with 100 µCi of 35S-Met (Perkin Elmer) in Cys/ 
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Met-free DMEM. When indicated, cells were washed and incubated with ice-cold 
PBS and then lysed in RIPA buffer (pH 7.4) containing protease inhibitors 
(Roche). Lysates were immunoprecipitated overnight with anti-GFP, boiled in 
SDS sample buffer with 0.1 M DTT, and analyzed by Tris-Acetate SDS-PAGE. 
Histological analysis - All tissues were fixed 96hrs at 4 degree in 
4% Formaldehyde solution in PBS, transferred to 30% sucrose in PBS, 
processed, and sectioned. For immunohistochemical staining, tissue underwent 
antigen retrieval in boiling citrate-based buffer (0.01#mol/L citric acid, pH 6.8). 
Endogenous peroxidases were quenched with 3% H2O2, followed by blocking in 
5% goat serum and incubation with primary antibodies (anti-Huntingtin 1:250, 
sc8767, Santa Cruz Biotechnology). Bound antibodies were detected with the 
Vector M.O.M. peroxidase (Vector Laboratories, Burlington, CA), using 
SigmaFast diaminobenzidene as a peroxidase substrate (Jackson 
ImmunoResearch, West Grove, PA). 
Primary neuron culture and transfection - Cortical neurons were dissected 
from P0 WT or Ube2W KO pups and cultured at 0.6 × 106 cells per milliliter for 4 
d in vitro before transfection, as described previously(191). Transfection of 
primary neurons was performed using Lipofectamine 2000 (Invitrogen). A total of 
0.2 µg DNA (total) and 0.5 µL Lipofectamine 2000 was used per well in 96-well 
plates. Cells were incubated with Lipofectamine/DNA complexes for 20 min at 
37 °C before rinsing and changing to normal culture media. Rest of the 
transfection was performed according to manufacture recommendation. 
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Automated fluorescence microscopy – Cultured primary mouse neurons 
were imaged by automated fluorescent microscopy (188–190, 192). The system 
is consisted of an inverted microscope (Nikon Eclipse Ti) equipped with the 
Perfect Focus System (Nikon), a high-numerical aperture 20× objective lens, a 
digital camera, a Lambda XL lamp (Sutter) and an ASI MS2000 stage to 
automatically control the platform. Neurons were imaged inside a thermo 
chamber, in which temperature and CO2 concentration was maintained at 37oC 
and 5% respectively. 
Image analysis – 25 raw images were taken from each well of primary 
neurons. Raw images were stitched together to represent a larger area. 
According to the sequence and alignment, stitched images were stacked 
together to represent time-elapse change of fluorescence. Neuronal survival was 
calculated by a software algorithm developed in ImageJ (192). The time of death 
for each neuron was recorded as the last time a neuron was confirmed to be 
alive (left censoring). Intensities of transfected proteins were determined 
automatically in Fig 3 by segmentation of neuronal cell bodies in ImageJ and 
measurement of mean pixel intensity within each region of interest. Statistical 
analyses and the cumulative hazard plots were generated using custom-written 
scripts and the survival package within R (192). 
RNA extraction and qRT-PCR - RNA was extracted from frontal brain of 
mice using TRIzol® (Life Technologies) and further purified using the RNeasy kit 
with on-column DNase I digestion (Qiagen). For qPCR, 1 µg of RNA was 
reverse-transcribed using iScript™. 0.5 µl was used with the SYBR® 
! 88#
GreenMasterMix and each reaction was performed in triplicate. qRT-PCR was 
performed on the Bio-Rad iCycler with MyIQ single color real-time PCR detection 
system module with the following parameters: 95°C at 3 min, (95°C 10 s, 55°C 
30 s) Å~ 40, 95°C 1 min, 55°C 1 min. The fold change in transcript levels was 
calculated using the ΔΔCt method(193). Gapdh was used as controls. The 
primers used for qRT-PCR are listed above. For figure 6A and 6B, qRT-PCR was 
performed with TaqMan® Gene Expression Master Mix (#4369016, Life 
technologies). qRT-PCR was performed on the applied biosystems 7500 real-
time PCR system and the remainder of the transfection protocol was per the 
manufacturer’s suggestions. Primers used for TaqMan qRT-PCR are from Life 
technologies (Drd2: Mm00438545_m1, Ppp1r1b: Mm00454892_m1 and Actb: 
Mm00607939_s1). 
 
3.4 RESULTS 
Ube2W regulates Htt inclusion formation in cultured cells 
Httex1Q103-GFP overexpression in HEK293 cells results in nuclear 
inclusion formation (Fig 15A). Visualized by fluorescence microscope, the 
formation of GFP-positive Htt inclusions was studied when Ube2W or its mutants 
were co-expressed with Httex1Q103-GFP. C91 is Ube2W’s enzymatic active site 
cysteine. Mutating C91 to alanine results in failed Ub transfer to substrate while 
still allowing Ube2W to bind substrate. Amino acid W144 lies near the C-terminus 
of Ube2W, and is critically important for substrate binding. Mutating W144 to 
glutamic acid results in failed substrate binding while retaining Ube2W’s capacity 
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as an enzyme since its active site cysteine remains(68). Both mutants are 
predicted to disrupt Ube2W-mediated Httex1Q103 ubiquitination. When WT Ube2W 
is co-expressed with Httex1Q103, inclusion number and size are significantly 
increased. In contrast, when either Ube2W mutant is co-expressed with 
Httex1Q103, inclusion number and size are significantly decreased (Fig 15). Neither 
Ube2W nor its mutants alters cell viability (data not shown).  
Biochemically, mutant Htt exists in three distinct states in cells: soluble 
monomers, soluble oligomers and insoluble aggregates(194, 195). Accordingly, 
lysates from transfected cells were separated into soluble and insoluble fractions 
based on solubility in a nonionic detergent (0.5% Triton-X100). Coexpression of 
the Ube2W mutant, W144E, dramatically increases soluble monomeric Htt. WT 
Ube2W results in a trend toward decreasing Htt soluble monomers, while the 
Ube2W mutant, C91A, shows a trend toward increasing Htt soluble monomers, 
although these did not reach statistical significance (Fig 16A and C). In the 
insoluble fraction, Htt exists as two species that are discernible by gel 
electrophoresis: high molecular weight (HMW) Htt in the stacking gel and 
monomeric Htt in the resolving gel. Both Ube2W mutants, W144E and C91A, 
significantly reduced levels of HMW and monomeric Htt in the insoluble fraction. 
In contrast, Ube2W overexpression showed no statistically significant change in 
levels of HMW or monomeric Htt in the insoluble fraction (Fig 16A, D and E).  
 
Ube2W does not alter Htt translation in cultured cells 
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To study whether Ube2W affects htt synthesis or degradation, I measured 
Htt translation using 35S-Methionine pulse-labeling. HEK293 cells overexpressing 
Httex1Q103 with WT Ube2W or the C91A mutant were pulse-labeled for 20 mins 
with 35S-Methionone to label all newly synthesized proteins. Labeling efficiencies 
were similar among different cell populations. After the 20 mins labeling and cell 
lysis, anti-GFP immunoprecipitation (IP) captured the soluble Httex1Q103-GFP 
present in cell lysates and the radioactive signal representing newly synthesized 
Htt was visualized by autoradiography. The rate of Httex1Q103 translation was 
similar regardless of which form of Ube2W was coexpressed (Fig 16B and F). 
Due to Htt’s tendency to aggregate over time, a pulse labeling followed by long 
chase times is technically difficult due to the inability to assess the aggregated 
Htt species by gel autoradiography.  
 
Ube2W deficiency results in decreased Htt inclusion formation and reduced 
neurotoxicity 
To investigate the consequences of Ube2W deficiency in vivo, I generated 
primary neuronal cultures from WT or conditional Ube2W KO mice in which the 
Nestin promoter results in Ube2W deletion in the nervous system. To assess the 
potential relationship between Ube2W and Httex1Q72-mediated neurotoxicity, I 
measured single-cell fluorescence and cell survival by automated fluorescence 
microscopy (AFM)(188–190, 192, 195). Using longitudinal AFM, I determined the 
risk of death for neurons expressing EGFP alone (as a control), normal repeat 
Httex1Q17-EGFP, or expanded repeat Httex1Q72-EGFP. AFM measures the 
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lifespan of individual neurons and gauges the impact of prespecified factors on 
the risk of death. The qualitative measures used to estimate cell death in these 
assays, loss of mApple fluorescence or disruption of cell integrity, are equally 
sensitive as conventional measures such as additional staining for apoptotic 
markers (195)(Fig 17A). I calculated risk of death for each population of neurons 
through Cox proportional hazards analysis, resulting in a hazard ratio (HR) 
analogous to measurements of relative risk in human clinical trials. Upon simple 
EGFP overexpression, neurons lacking Ube2W showed significantly increased 
neuronal cell death compared to neurons expressing Ube2W. In contrast, upon 
expression of mutant Httex1Q72-EGFP, neurons lacking Ube2W showed a 
statistically significant reduction in risk of death. Importantly, Ube2W KO neurons 
did not show a significant difference in risk of death from expression of Httex1Q17-
EGFP overexpression (Fig 17B).  
 To assess the effect of Ube2W on EGFP or Httex1 expression levels, I 
measured the fluorescence signal separately in each of hundreds of EGFP- or 
Httex1Qn-EGFP-expressing neurons 24 hours after transfection, a time when 
Httex1Q72-EGFP inclusion body formation is minimal. In neurons expressing 
EGFP alone, EGFP fluorescence did not differ between WT and Ube2W KO 
neurons. In contrast, the absence of Ube2W resulted in significantly decreased 
fluorescence signal for both Httex1Q17-EGFP and Httex1Q72-EGFP (Fig 17C-E). To 
further study Ube2W’s effect on Htt inclusion formation, I quantified Httex1Q72-
EGFP inclusion formation in transfected neurons. The number of neurons with 
Httex1Q72-EGFP inclusions was decreased by 20% in the absence of Ube2W  (Fig 
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17F). These inclusion-negative neurons showed diffuse EGFP signal that 
persisted to the endpoint of the experiment (216hr).  
 
Ube2W deficiency increases soluble monomeric HttQ200  
 To further study Ube2W’s effect on mutant Htt in vivo, heterozygous 
HdhQ200 KI mice were crossed with Ube2W germline KO mice. At 32 weeks of 
age, frontal brain lysates including the striatum, the most involved region in HD, 
were prepared in RIPA buffer and separated by gel electrophoresis. Strikingly, 
soluble mutant HttQ200 monomers were significantly increased by approximately 
5-fold in the absence of Ube2W (Fig 18A and C). A similar increase in soluble 
HttQ200 was also observed in 46 week-old in Ube2W KO mice (data not shown). 
Moreover, in HdhQ200 KI mice, the absence of Ube2W caused an increase in WT 
Htt monomers by approximately 3 fold (Fig 18A and B). In comparison, Ube2W 
KO mice not crossed to HdhQ200 KI mice failed to show any change in WT Htt 
levels. Thus, the increase in WT Htt in Ube2W-/-, HdhQ200 mice appears to be 
secondary to coexpression of mutant HttQ200. In these experiments, in which 
RIPA buffer was the lysis buffer and analyzed by SDS-PAGE, no Htt signal was 
observed in the stacking gel, which would represent detergent-resistant HMW Htt 
species.  
To exclude the possibility that the observed changes reflected 
transcriptional differences, I investigated whether Ube2W affects Hdh 
transcription (both WT and mutant) by qRT-PCR. Ube2W deficiency did not alter 
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Hdh transcript level, arguing that Ube2W instead affects Htt expression at a 
translational or post-translational stage (Fig 20C). 
 
HttQ200 inclusion bodies in striatum are not altered by Ube2W deficiency 
Inclusion bodies in neurons are a pathological hallmark of HD. Due to 
polyQ expansion, HttQ200 forms widespread neuronal inclusion bodies in striatum, 
cortex, hippocampus and cerebellum of HdhQ200 KI mice, beginning at ~32 
weeks of age. To determine whether the marked increase in HttQ200 monomers 
correlated with a change in size or number of inclusion bodies, I performed 
immunostaining with an N-terminal Htt antibody on brain sections from 32 and 46 
week old mice (Fig 19A and B). At 46 weeks old, striatum of both groups showed 
robust presence of inclusion bodies with no significant difference in inclusion 
number or size in the presence or absence of Ube2W (Fig 19C and D). This 
result suggests that Ube2W preferentially affects levels of soluble HttQ200 without 
altering levels of insoluble, aggregated disease protein. 
 
Ube2W deficiency does not alter transcript levels of striatal markers in 
HdhQ200 mice 
Medium spiny neurons in striatum are the most affected neuronal 
population in HD and are known to be affected in HdhQ200 mice. Expression 
levels of two striatal neuronal markers, Dopamine D2 receptors (Drd2) and 
DARPP-32 (Ppp1r1b), decline dramatically over the course of disease in human 
HD patients and animal models(186, 196–199). Their transcript levels have been 
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shown to be sensitive measurements of HD pathology in mice(127). Indeed, at 
46 weeks of age transcript levels for both markers decreased significantly in 
HttQ200 het KI mice, suggesting striatal neuronal dysfunction(127, 200). Ube2W 
deficiency failed to lead to a significant alteration in transcript levels of these 
striatal markers (Fig 20A and B). Thus, the presence or absence of Ube2W does 
not appear to affect the degree of HttQ200-mediated striatal neuron dysfunction.  
 
Levels of key molecular chaperones are unchanged in Ube2W KO mice 
Protein chaperones and protein-folding machinery are important 
regulators in mutant Htt processing and HD pathology (as discussed in Chapter 
1). Accordingly, I sought to determine whether the Ube2W-mediated increase in 
HttQ200 monomers reflects a change in key components of the protein-folding 
machinery. The heat shock protein (hsp) family is a group of proteins implicated 
in correct protein folding. I measured expression levels of four members of hsp 
family: hsp40, hsp60, hsp70 and hsp90. Only hsp70 showed a decrease in 
Ube2W-/-, HdhQ200 mice; other hsp family members were not significantly altered 
(Fig 21). A decrease in hsp70 has been reported in various HD mouse models, 
however, whether it correlates with HD progression is not fully understood(186, 
201). These results argue that Ube2W deficiency does not cause the observed 
increase in HttQ200 monomers simply by changing levels of key quality control 
molecular chaperones. 
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3.5 DISCUSSION 
 Htt normally is highly disordered at the N-terminus. In HD, where polyQ 
expansion occurs 18 amino acids into the protein coding sequence, the degree of 
disorderness of Htt is further increased and the disordered disease protein tends 
to misfold, aggregate and accumulate as inclusion bodies (IBs). Ubiquitin 
pathways have been shown to regulate Htt levels, IB formation and disease 
progression(144, 145, 114, 112, 113, 143, 202, 203). Given its highly disordered 
N-terminus, Htt is predicted to be a candidate substrate of Ube2W N-terminal 
ubiquitination. However, such non-canonical ubiquitination of Htt has not been 
studied before. In this chapter, I utilized different model systems to show that 
Ube2W deficiency leads to increase in soluble Htt levels, while reducing 
aggregation and neurotoxicity in cellular models. This study provides evidence 
supporting the importance of ubiquitin pathways in HD and in particular sheds 
light on the possible function of N-terminal ubiquitination of Htt.  
A decrease in Htt solubility is likely critically important to HD pathogenesis. 
As mentioned earlier, Htt can exist in three distinct states in cells: soluble 
monomers, soluble oligomers and insoluble aggregates(194, 195, 204). 
Preceding aggregation, Htt oligomers are considered to be a more toxic species 
than monomers and aggregates(194, 205–208). Using FRET confocal 
microscopy, researchers showed that neuronal cells containing oligomers die 
faster than those with either monomers or inclusions(194). In drosophila, 
polyphenol epigallocatechin-gallate reduces oligomeric species by promoting 
inclusion formation with a corresponding protective effect towards Htt 
! 96#
neurotoxicity(206). In contrast to toxic oligomers, Htt insoluble aggregates have 
protective effects by recruiting and neutralizing toxic oligomers(191, 194, 195, 
209, 210) (Fig 5).  
Htt monomers are generally believed to be non-toxic species, however, 
there is limited in vivo evidence to support this argument(194). In this chapter, I 
observed a significant increase in Htt monomers when Ube2W is deficient or 
absent, accompanied by increased neuronal survival in cultured cells (Fig 15, 16 
and 17). This evidence suggests an inverse correlation between monomeric Htt 
levels and cytotoxicity. The increase in Htt monomers observed here could result 
from reduced oligomerization of monomers or solubilization of Htt oligomers, with 
the cytoprotective effect achieved by indirectly decreasing toxic oligomers. In 
order to prove this hypothesis, further experiments are proposed to visualize Htt 
oligomers. In cellular models where HD is modeled by Httex1 overexpression, a 
combination between split fluorescence tagging (such as bimolecular 
fluorescence complementation, BiFC) and time-lapse confocal microscopy allows 
visualization and quantification of Htt oligomers specifically(211). Furthermore, 
oligomers can be visualized using biochemical approaches: filter retardation 
assays and SDS-agarose gel can determine Htt oligomers by their characteristic 
high molecular weight. More detailed approaches are discussed in future 
directions in chapter 4. To conclude, Ube2W deficiency leads to increased Htt 
monomers and reduced cytotoxicity. This study provides evidence supporting the 
view that Htt monomers are relatively non-toxic species.  
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 What is the mechanism by which Ube2W alters solubility of mutant Htt? I 
have considered three hypotheses: 1. N-terminal ubiquitination of Htt is a 
stabilizing signal that contributes to Htt aggregation; 2. N-terminal ubiquitination 
of Htt alters other post-translational modification(s) of Htt N-terminus, thus 
indirectly promoting Htt aggregation; and 3. Ube2W ubiquitinates other proteins 
that regulate Htt, such as SUMO-2, a documented Ube2W substrate that 
increases Htt aggregation(145). At the time of thesis defense, I am still in the 
process of investigating these individual hypotheses.  
The exact biological role of Ube2W-mediated ubiquitination is not fully 
understood. Based on limited studies, a role in proteasomal degradation has 
been proposed. As discussed in chapter 1, researchers have identified at least 
13 proteins that can be N-terminally ubiquitinated(56, 58, 52, 158, 53, 51, 62, 55, 
60, 61). All but two known N-terminal substrates (ataxin-3 and LMP2A) are 
targeted for proteasomal degradation by N-terminal ubiquitination via lys48-linked 
polyubiquitination. Additionally, in chapter 2, I showed an accumulation of 
disordered proteins in Ube2W KO testis, indicating that Ube2W-mediated N-
terminal ubiquitination likely functions as a degradation signal. A derivative form 
of N-terminal ubiquitination further supports this hypothesis. Specifically, an N-
terminal mutant ubiquitin fusion has been widely used as a “degron” that targets 
the protein for degradation by the UPS. For example, UbG76V-GFP can be used 
as a proxy of UPS activity due to its rapid proteasomal degradation(108, 110, 
109, 212). The G76V mutation inhibits Ub removal from substrates by DUBs and 
allows subsequent polyubiquitination(108). This evidence indicates that N-
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terminal ubiquitination of GFP serves as a signal for proteasome degradation. 
These lines of evidence suggest that Ube2W-mediated N-terminal ubiquitination 
can target proteins for degradation. However, because Ube2W is a strict 
monoubiquitinating enzyme, it does not determine subsequent Ub chain 
linkage(5, 25, 56, 68, 69). As reviewed in chapter 1, cellular functions of 
ubiquitination are not limited to degradation pathways. Working with 
Ube2N/Ube2V2, Ube2W is able to generate K63-linked ubiquitin chains on 
TRIM5α and TRIM21. Such non-proteolytic K63-linked polyubiquitination is 
critical to regulating the reverse transcription activity of TRIM5α and TRIM21(69, 
70). Accordingly, the potential functions of N-terminal ubiquitination in non-
degradative pathways cannot be ruled out. Further studies are required to 
identify the Ub chain linkages of Htt N-terminal ubiquitination and its biological 
function with respect to Htt solubility. 
Besides direct N-terminal ubiquitination, alternative mechanisms, such as 
SUMOylation, can also cause alteration in Htt monomers. SUMO-2 itself can be 
N-terminally monoubiquitinated by Ube2W in vitro(67), though the biological 
function of this signal is still unknown. It is possible that Ube2W ubiquitinates 
SUMO-2 already conjugated to Htt. SUMO-2 modification of Httex1 decreases Htt 
solubility: it favors Htt accumulation and decreases monomers(145). Similar to 
the findings here with Ube2W mutants, SUMO-2 knockdown in cells significantly 
decreases insoluble Htt species. Based on this finding, it is likely that Ube2W-
mediated N-terminal ubiquitination on SUMO-2 is a prerequisite for Htt 
SUMOylation. Thus inhibiting Ube2W would cause the same effect as abolishing 
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SUMO-2. Further studies will be important to address this alternative hypothesis 
(see also chapter 4). 
While more work remains, my studies on Ube2W and HD have begun to 
provide insight into how the ubiquitin system can regulate misfolded proteins 
contributing to diseases. 
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3.6 FIGURE LEGENDS 
FIGURE 15. Ube2W alters Httex1Q103-GFP inclusion formation in HEK293 cells 
Httex1Q103 inclusion is visualized by GFP fluorescence with co-overexpression of 
vector (A), Ube2W (B), W144E (C) and C91A (D). Scale bar=30 µm. 
Httex1Q103 inclusion number (E) and size (F) from all four groups were plotted. 
Graphs show means +/- SEM; ***, p<0.001; ****, p<0.0001. n=8 (E), n>34 (F). 
 
FIGURE 16. Ube2W alters solubility of Httex1Q103 
A. Western Blot of lysates from cells transfected with Httex1Q103 and Ube2W or its 
mutants, W144E and C91A. Upper panel is the Triton-X100 soluble fraction and 
lower panel is the Triton-X100 insoluble fraction. Blotted with anti-GFP 
(Httex1Q103), anti-tubulin-α and anti-Ube2W. (15 µg total protein loaded per lane.) 
Arrowheads indicate Httex1Q103, Ube2W or tubulin, and bracket indicates high 
molecular weight Httex1Q103 in stacking gel. 
B. Autoradiograph of a representative 35S-methionine pulse-chase experiment 
followed by GFP-IP and gel electrophoresis. Arrowhead indicates Httex1Q103 
signal. 
C-E. Quantification of Western Blot in panel A. Graphs show means +/- SEM; ns, 
not significant; *, p<0.05; ***, p<0.001; ****, p<0.0001. n=3. 
F. Quantification of autoradiograph in panel B. Graphs show means +/- SEM; ns, 
not significant. n=3. 
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FIGURE 17. Ube2W deficiency results in decreased Httex1Q72 inclusion formation 
and increased neuronal survival 
A. Representative images from automated fluorescence microscopy. Primary 
cortical neurons from WT and Ube2W KO mice were transfected with mApple 
and Httex1Q72-EGFP, and survival was determined by repeated imaging at regular 
intervals. The last time at which the cell was noted to be alive (red arrows) was 
used as the time of death. Cells that survive the entire length of the experiment 
(blue arrow) were censored (analyzed as living cell at the end of experiment). 
Scale bar=25 µm.  
B. Cumulative risk of death over time for WT and Ube2W KO neurons 
transfected with EGFP, Httex1Q17-EGFP and Httex1Q72-EGFP. Results were 
pooled from 16 wells per condition, with experiments performed in duplicate. 
C-F. Quantification of EGFP signals or inclusion formation from experiments in 
panel A. Graphs show means +/- SEM; ns, not significant; *, p<0.05. n>232. 
 
FIGURE 18. Ube2W deficiency increases soluble Htt levels in HdhQ200 KI mice 
A. Western Blot of mouse frontal brain lysates from WT, Ube2W KO, HdhQ200 
heterozygous (het) KI, HdhQ200 het KI with Ube2W KO mice. Blotted with anti-Htt, 
anti-polyQ, anti-Ube2W and anti-GAPDH antibodies. (40 µg total protein loaded 
per lane.) Arrowheads represent mutant HttQ200; arrow represents WT Htt.  
B and C. Quantification of Western Blot in panel A. Graphs show means +/- SEM; 
ns, not significant; *, p<0.05; **, p<0.01. n=3. 
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FIGURE 19. Absence of Ube2W does not alter HttQ200 inclusion levels in 
striatum of HdhQ200 KI mice
A and B. Htt immunostaining of striatum showing HttQ200 intranuclear inclusions 
in 46 weeks old HdhQ200 het KI, HdhQ200 het KI with Ube2W KO mice. Inserts 
show magnified region represented on the left panel. Scale bar on the left 
panel=200 µm; Scale bar of insert=50 µm. 
HTTex1Q103 inclusion number (C) and size (D) from both 32 weeks and 46 weeks 
old mice of both groups were plotted. Graphs show means +/- SEM; ns, not 
significant. n=10 (C), n>10 (D). 
 
FIGURE 20. Ube2W deficiency does not alter transcript levels of striatal neuronal 
markers in HdhQ200 KI mice. 
Dopamine receptor 2 (Drd2) (A), DARPP-32 (Ppp1r1b) (B) and Huntingtin (Hdh) 
(C) transcript levels are measured by qRT-PCR amplification. RNAs were 
extracted from WT, HdhQ200 het KI, HdhQ200 het KI with Ube2W KO mice frontal 
brains. Results are normalized to β-actin (Actb) levels. Results were quantified 
and plotted as graphs. Graphs show means +/- SEM; ns, not significant. n=4.  
 
FIGURE 21. Ube2W deficiency does not cause significant changes in levels of 
major chaperone proteins. 
A. Western Blot of mouse frontal brain lysates from WT, Ube2W KO, HdhQ200 het 
KI, HdhQ200 het KI with Ube2W KO mice. Blotted with anti-Hsp40, anti-Hsp60, 
anti-Hsp70and anti-Hsp90 antibodies. (40 µg total protein loaded per lane.) 
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B-E. Quantification of Western Blot in panel A. Graphs show means +/- SEM; ns, 
not significant; *, p<0.05; n=3. 
 !
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Chapter Four: Conclusions and future directions 
 
In the previous three chapters, I investigated the biological functions of 
Ube2W and N-terminal ubiquitination. In chapter 1, I reviewed different ubiquitin 
pathways and their involvement in the pathogenesis of Huntington’s disease. In 
chapter 2, I explored the potential in vivo functions of Ube2W, a N-terminal 
ubiquitinating E2, utilizing a novel Ube2W KO mouse model. I found that Ube2W 
plays an important function in mouse early post-natal survival, epidermal 
differentiation, and in the immune and male reproductive systems. In chapter 3, I 
investigated Ube2W’s function in a prototypical protein-misfolding 
neurodegenerative disease, Huntington’s disease; I showed that Ube2W 
regulates soluble level of Htt. In this final chapter, I discuss potential future 
studies building on the results of chapters 2 and 3, which should provide further 
insight into the biological functions of Ube2W-mediated N-terminal ubiquitination. 
 
4.1 Ube2W involvement in skin differentiation 
The sequential differentiation of epidermis is essential for post-natal 
survival. The loss of keratohyalin granules and altered Loricrin immunostaining in 
Ube2W KO P0 mice suggest a defect in barrier function, which can result in early 
postnatal lethality due to excessive water loss (reviewed in 37, 38). A similar 
phenotype was reported in other mouse models: for example, transient 
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knockdown of filaggrin, component of keratohyalin granules, results in reduced 
number of keratohyaline granules and reduced stratum corneum thickness(213); 
Filaggrin-null mice show a loss of skin barrier integrity analyzed by 
immunostaining and transepidermal water loss assay(214, 215). Detailed studies 
of skin barrier function and keratohyalin granule components in Ube2W KO mice 
will be helpful to further characterize the skin defect.  
In Ube2W KO mice, the 60% postnatal lethality we observe is a similar 
percentage to that of the altered skin phenotype, suggesting a potential link 
between the epidermal differentiation defect and early postnatal lethality. In order 
to establish a direct cause-effect relationship between the skin defect and early 
postnatal lethality, I have already begun experiments to delete Ube2W selectively 
in epidermis using tissue-specific Cre-Lox recombination. Keratin-5 promoter-
driven Cre expression results in confined Ube2W deletion in basal cell layer, and 
thus after epidermal differentiation, all epidermal layers will be deficient of 
Ube2W(216). By the time of my thesis defense, given the limited number of mice 
recovered I cannot yet reach a conclusion. If the same percentage of lethality 
and skin defect is observed in K5-driven Ube2W KO mice, it will suggest that 
Ube2W causes mouse early postnatal lethality due to a defect in skin 
differentiation.  
 
4.2 Identification of N-terminal ubiquitin-modified proteome  
 To further investigate the function of N-terminal ubiquitination, more 
substrates should be identified and studied. The current identification of N-
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terminal ubiquitination substrates has relied on two key methods: 1) mass 
spectrometry to identify fusion peptides directly linking the C-terminal glycine of 
Ub to the N-terminal methionine of the substrate; and 2) in vitro ubiquitination 
assays in which candidate substrates are mixed with E1, E2, E3, Ub and ATPs. If 
lysine-less substrate can still be ubiquitinated and blockade of α-amino group can 
abolish ubiquitination, the tested substrate is considered a N-terminal 
ubiquitination target. However, both methods identify targets individually instead 
of globally. Global identification of N-terminal ubiquitination targets performed in 
an unbiased manner would greatly facilitate future studies of the function of N-
terminal modification.  
The canonical ubiquitin-modified proteome has been widely studied in the 
past decade(217–220). Trypsin digestion of an ubiquitin-conjugated protein 
produces a signature peptide at the ubiquitination site containing a two-residue 
remnant (glycine-glycine) that is derived from the C terminus of ubiquitin and is 
still covalently attached to the target lysine residue via an isopeptide bond. This 
signature peptide (GGK) has a mass shift at the lysine residue of 114.1 Da, as 
well as a missed proteolytic cleavage because trypsin proteolysis cannot occur at 
these modified lysines. Due to this feature, ubiquitinated substrates can be 
identified by mass spectrometry(220). Under the same basis, monoclonal 
antibody derived from the signature peptide GGK can capture the ubiquitinated 
proteins by immunoprecipitation(217–219). The antibody is specific to Ub-
modified lysines instead of linear peptide bond-linked lysines.  
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However, the systematic detection of N-terminal ubiquitination is more 
complicated. In the cellular microenvironment, a process called N-terminal 
methionine excision happens to approximately 60-70% of proteins(221). During 
this process, methionine aminopeptidase cleaves the N-terminal methionine, thus 
the new protein starts with the second amino acid(222, 223). Among the 30-40% 
of proteins whose starting methionine remains intact, a majority will be acetylated, 
physically blocking the N-terminus from ubiquitination. Accordingly, only 14-22% 
of proteins are predicted to be potential candidates for acquiring the signature 
peptide (GGM) seen upon N-terminal ubiquitination. In addition, unlike canonical 
lysine ubiquitination, the linkage between the ubiquitin C-terminus and N-terminal 
methionine is linear. Hence the linkage sequence GGM does not differ from 
GGM derived from internal protein sequences. The three-peptide sequence is too 
short to identify any protein specifically. 
Since currently there is no specific method to identify fusion peptides of N-
terminal ubiquitination, indirect methods have to be used. One possible 
alternative strategy is to utilize Ube2W KO cells or mice. Since Ube2W is the 
only E2 known to carry out N-terminal ubiquitination, deletion of Ube2W should 
abolish such ubiquitination. For N-terminally ubiquitinated substrates, the N-
terminal protein sequence will differ in the presence or absence of Ube2W: the 
protein’s N-terminus would start with ubiquitin in the WT proteome but with its 
own N-terminus in the Ube2W KO proteome. Protein N-terminus profiling 
enables these changes to be identified by mass spectrometry. There are both 
positive and negative selection methods to identify protein N-termini.  
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Strategies for positive selection in N-terminus profiling involve chemical or 
enzymatic tagging of protein N-termini before trypsination. For example, biotin 
can be tagged to the N-termini of proteins by a modified subtiligase; after 
trypsination, an avidin column captures biotin-ligated N-terminal peptides. The 
attached biotin can be cleaved by the tobacco etch virus (TEV) protease(224). 
However, positive selection has its limitations: 1) it is highly dependent on 
complete ligation efficiency and subtiligase specificity, especially when 
comparing protein abundance among different samples(225, 226); and 2) it can 
only identify free protein N-termini instead of naturally modified N-termini such as 
with acetylation. 
Negative selection removes internal peptides, thus enriching both free and 
modified N-terminal peptides. The protein’s α-amino group is first protected either 
by acetylation or dimethylation, followed by trypsin digestion to generate internal 
peptides with unprotected N-terminal amines. Using different methods, these 
newly generated internal peptides can be removed. Protected N-terminal 
peptides are preserved and can be sequenced thereafter. These negative 
selection approaches include: Combined Fractional Diagonal Chromatography 
(COFRADIC), Dimethyl Isotope-Coded Affinity Selection (DICAS), Terminal 
Amine Isotope Labeling of Substrates (TAILS), and phosphor tagging(225, 227–
229). 
Taken together, a combination of protein N-terminal profiling and stable 
isopeptide labeling (such as the TMT-labeling used in Chapter 2) can 
quantitatively assess the abundance of N-terminal peptides. Comparison 
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between the WT and Ube2W KO N-terminome will globally identify N-terminal 
ubiquitinated proteins and facilitate the functional study of such modification. 
 
 
4.3 Protamine-2 as a potential target for Ube2W N-terminal ubiquitination 
 Consistent with the recent view that Ube2W may preferentially target 
substrates with disordered N-termini, our bioinformatic analysis revealed an 
accumulation of proteins with increased disorder in Ube2W KO testis. Protamine-
2, an intrinsically disordered testicular protein, was confirmed by Western blot 
analysis to be increased in the absence of Ube2W. The N-terminus of protamine-
2 is highly disordered: it starts with a continuous length disorder (CLD) region 
and 80% of its amino acids are disordered according to both IUPRED and 
DisEMBL prediction algorithms. Protamines are DNA binding proteins that are 
critical for testicular function. The association between DNA and protamines 
leads to substantial molecular remodeling and ultimately to 10-fold compaction of 
the male genome into toroidal nucleoprotamine structures. Protamines facilitate 
the hydrodynamic shape of the sperm head and protect the paternal genome 
from physical and chemical damage(230). In mature spermatozoa, about 85% of 
histones are replaced by the protamine-1 and protamine-2 in humans. Compared 
to the 51-amino-acid long protamine-1, the 107-amino-acid protamine-2 is twice 
the size, yet has fewer post-translational modifications. Protamine-1 is acetylated 
on the N-terminus amine, which potentially blocks other modifications, whereas 
protamine-2 retains a free α-amino group(231). Collectively this information 
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suggests that protamine-2 is a strong candidate target for Ube2W. Further 
experiments should be performed to validate this idea: 1) in vitro ubiquitination 
assay to prove that lysine-less mutant protamine can be ubiquitinated, and that 
blocking its N-terminus can abolish ubiquitination; 2) protamine-2 enrichment 
followed by mass spectrometry should identify the signature peptide of Ub 
modification on the protamine-2 N-terminus; and 3) cell-based experiments to 
study whether protamine-2 ubiquitination and degradation are altered by Ube2W 
overexpression or knock-down.  
 
4.4 Ube2W’s effect on insoluble Htt and HD disease progression 
 In chapter 3, I showed that Ube2W deficiency results in an increase of 
soluble Htt monomers in Htt KI mice, without significantly altering inclusion 
formation and HD severity at 32 weeks of age. As discussed in chapter 1, mutant 
Htt protein tends to misfold and accumulate in cells. Such accumulation can 
present as inclusion bodies or oligomers. When I analyze Htt expression by 
Western blotting, protein lysates are first denatured by detergents. This process 
generates two fractions of Htt: detergent-soluble and detergent-insoluble. A 
complete analysis of both fractions will help us understand the precise function of 
Ube2W with respect to Htt solubility and clearance 
Currently there are two common methods to analyze the Htt insoluble 
fraction: 1) filter retardation assay (dot blot) where protein lysates are run through 
micropores on a cellulose acetate membrane trapping the insoluble material on 
the membrane (flow-through containing soluble Htt is discarded). 2) the use of 
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stronger detergents to further denature insoluble Htt (usually 4% SDS and 
30mins boiling) and allow visualization of insoluble fraction by Western blotting. I 
hypothesize that Ube2W-driven N-terminal ubiquitination of Htt is a stabilizing 
signal that promotes Htt oligomer formation. When Ube2W is knocked-out in HD 
KI mice, the loss of this stabilizing signal triggers Htt to solubilize, leading to an 
increase in soluble Htt and a decrease in oligomeric, insoluble Htt. However, if 
the absence of Ube2W results in an increase in both soluble and insoluble Htt 
fractions, it would suggest that Ube2W mediates Htt clearance. This possibility is 
supported by the study in chapter 2 that showed a preferential accumulation of 
disordered protein in Ube2W KO testis, implying that Ube2W-mediated N-
terminal ubiquitination can be a degradation signal.  
Whether mutant Htt is indeed N-terminally ubiquitinated in vivo is still 
unknown. Given the published in vitro data(68), Htt is a compelling target for 
Ube2W. Mass spectrometry confirmation of Ube2W-driven N-terminal 
ubiquitination of Htt will be important to establish it as an actual target. The 
existence of signature peptide for N-terminal modification in WT brain, while 
missing in Ube2W KO brain, would prove that Ube2W indeed ubiquitinates Htt’s 
α-amino group. However achieving this requires a clean immunoprecipitation (IP) 
of Htt, which is challenging since most mutant Htt exists as insoluble species that 
are not easily accessible to antibodies in an IP experiment. To address this issue, 
one could examine a different organ other than brain. As discussed earlier, the 
Htt mutation is present in every cell in the body although inclusion formation and 
signs of cytopathology are limited to nervous system. In other organs, Htt is more 
! 119"
soluble and accessible to IP antibodies. So, a Htt-IP from non-neuronal tissues 
followed by mass spectrometry might provide direct evidence for Htt N-terminal 
ubiquitination.  
As introduced in chapter 1, mutant Htt accumulation is enhanced by Htt 
SUMOylation on K6 and K9 by PIAS1(144, 145). If Ube2W adds a bulky 8.5kDa 
ubiquitin to Htt’s crowded N-terminus, such N-terminal ubiquitination conceivably 
could block or alter other modifications on Htt near the N-terminus (Fig 5). 
Moreover, SUMO-2 itself can be N-terminally ubiquitinated by Ube2W(67). Thus, 
alteration of mutant Htt levels in Ube2W KO mice might be explained by a 
secondary effect on SUMO-2 ubiquitination. In order to test this hypothesis, Htt 
SUMOylation levels can be measured by SUMO enrichment followed by Htt 
blotting. Additionally, I could use cultured cells to study this hypothesis: a SUMO-
2 di-glycine mutation abolishes substrate binding, and thus if co-overexpression 
of this SUMO-2 mutant did not influence Ube2W’s effects on Htt levels, it would 
indicate Ube2W does not act on Htt primarily through a SUMO-2 dependent 
mechanism.
 
4.5 Concluding remarks 
Ubiquitin pathways are involved in many cellular processes and are 
implicated in a wide range of human diseases. N-terminal ubiquitination is easily 
missed by current methods, yet may play a key role in multiple organ systems. 
The recent identification of Ube2W as the only E2 that carries out N-terminal 
ubiquitination has helped to shed light on the potential roles of this noncanonical 
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ubiquitin pathway. My dissertation work explored the importance of this intriguing 
E2 in vivo, addressing its possible roles in different organ systems. It also 
provided in vivo support for the view that Ube2W preferably targets disordered 
substrates. Protein disorderness is implicated in protein-misfolding diseases such 
as Huntington’s disease. While more work remains, my studies on Ube2W and 
HD have begun to provide insight into how the ubiquitin system can regulate 
misfolded proteins contributing to diseases. Alterations of ubiquitin pathways 
have the potential to influence the processing and clearance of disease proteins. 
Thus, they represent potential therapeutic targets in a large class of protein-
misfolding diseases, many of which are currently untreatable and fatal disorders. !!! !
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